Introduction {#s1}
============

The precise positioning of each organ and tissue has to be tightly controlled during embryogenesis. The body plan along the anteroposterior axis is modulated by the spatiotemporal expression of *Hox* genes, which is known as the '*Hox* code' ([@bib97]; [@bib60]). Hox genes encode a family of transcription factors that contain a helix-turn-helix type homeodomain. In vertebrates, Hox genes are organized into four paralogous clusters (A to D) that can be divided into thirteen groups. The members of each paralogous group have partially redundant functions, but also acquire independent functions ([@bib97]; [@bib59]). During development, the paralogous group at the 3' end of the clusters is expressed in the anterior part of the body, while the more 5' genes are expressed in the more posterior part, towards the tail ([@bib18]; [@bib19]; [@bib20]; [@bib25]; [@bib26]; [@bib40]; [@bib39]). These expression patterns modulate the anterior and posterior axis and specify the regional anatomical identities of the vertebrae: Hox gene-knockout mice show anterior transformations where specific vertebrae mimic the morphology of a more anterior one ([@bib10]; [@bib9]; [@bib52]; [@bib12]; [@bib41]; [@bib83]; [@bib17]; [@bib34]; [@bib36]; [@bib35]; [@bib51]; [@bib16]; [@bib76]; [@bib86]; [@bib4]; [@bib23]; [@bib22]; [@bib5]; [@bib8]; [@bib7]; [@bib61]; [@bib91]; [@bib24]; [@bib95]; [@bib98]; [@bib63]). Multistage controls, such as transcriptional, posttranscriptional, and epigenetic regulation, are required for the nested expression patterns of *Hox* genes ([@bib60]).

As for epigenetic control, *Polycomb* group (PcG) genes are involved in *Hox* gene regulation via the chromatin architecture at *Hox* cluster loci in a developmental time-dependent manner ([@bib84]). PcG genes form two complexes, the *Polycomb* Repressive Complex (PRC) one and PRC2. PRC2 includes Ezh2, which can catalyze H3K27me3 at target loci, and consequently, this specific histone modification causes the recruitment of PRC1 via Cbx2 in the complex to silence gene expression. Thus, the accumulation of PcG complexes at *Hox* clusters during embryogenesis leads to the transcriptional silencing of *Hox* genes, which is supported by evidence that the ablation of PcG genes dysregulates *Hox* gene expression, resulting in subsequent skeletal transformation in anteroposterior patterning ([@bib60]; [@bib84]). During embryogenesis, PcG gene expression gradually diminishes ([@bib30]), which leads to the initiation of spatiotemporal *Hox* gene expression. However, the molecular mechanisms underlying the termination of PcG gene expression remain largely unclear.

Previously, we generated a whole-mount in situ hybridization database called 'EMBRYS' that covers \~1600 transcription factors and RNA-binding factors using mice at embryonic day (E)9.5, E10.5, and E11.5 ([@bib109]). Among these data, we were particularly interested in dynamic expressional changes of *Lin28a* during embryogenesis: at E9.5, *Lin28a* is expressed ubiquitously, whereas its expression gradually diminishes from head to tail at E10.5 and E11.5 ([@bib108]; [@bib109]). These unique expressional changes prompted us to analyze if *Lin28a* is involved in the spatiotemporal regulation of *Hox* genes.

*Lin-28* was identified as a heterochronic gene that regulates the developmental timing of multiple organs in *Caenorhabditis elegans* (*C.elegans*) ([@bib66]). *Lin-28* encodes an RNA-binding protein, and the loss of function of *Lin-28* causes precocious development, with skipping of events that are specific to the second larval stage ([@bib3]; [@bib66]). In contrast, mutants of *let-7*, a microRNA-encoding heterochronic gene, exhibit reiteration of the fourth larval developmental stage because of failures in terminal differentiation and cell-cycle exit ([@bib73]; [@bib77]). Importantly, *Lin-28* and *let-7* form a negative feedback loop that is essential for developmental timing in *C. elegans*. This reciprocal regulation between Lin28a and *let-7* is well conserved in mammals ([@bib67]; [@bib94]); Lin28a promotes the degradation of *let-7* precursors ([@bib33]; [@bib6]), whereas *let-7* inhibits *Lin28a* expression via posttranscriptional regulation ([@bib67]).

Vertebrates possess two homologs of *Lin28* genes, *Lin28a* and *Lin28b. Lin28a* is highly expressed in pluripotent stem cells and is ubiquitously expressed in the early embryonic stage, and its expression is diminished during development ([@bib106]; [@bib82]; [@bib108]; [@bib109]). In contrast, *Lin28b* is dominantly expressed in testes, placenta, and fetal liver, as well as in undifferentiated hepatocarcinoma ([@bib27]). The versatile functions of *Lin28a* are observed in diverse events, such as germ layer formation ([@bib21]), germ cell development ([@bib99]), neural development ([@bib105]), glucose metabolism ([@bib113]), and skeletal development ([@bib1]; [@bib78]; [@bib72]). Conversely, *let-7*-family genes are highly expressed in differentiated tissues, and their products function as tumor suppressors via the inhibition of oncogenes such as *c-Myc*, *K-ras*, and *Hmga2* ([@bib62]; [@bib53]; [@bib43]; [@bib80]). These observations prompted us to test the potential 'heterochronic' function of *Lin28a* in vertebrate development; however, it remains largely unclear if the evolutionally fundamental function of the *Lin-28* and *let-7* negative feedback loop in the regulation of developmental timing and pattern of *C. elegans* is conserved or adapted in vertebrates.

In this work, we generated *Lin28a* knockout (*Lin28a*^--/--^) mice and analyzed the function of this gene in developmental patterning. We showed that the *Lin28a*/*let-7* pathway is critical for axial elongation and vertebral patterning. *Lin28a*^--/--^ mice exhibited axial shortening with mild skeletal transformations of vertebrae, which were consistent with results observed in mice with tail bud-specific gain/loss of function of Lin28a ([@bib1]; [@bib78]). The accumulation of *let-7*-family microRNAs in *Lin28a*^--/--^ mice resulted in the reduction of PRC1 occupancy at the *Hox* cluster loci by targeting *Cbx2*. Consistent with these results, Lin28a loss in embryonic stem-like cells led to the aberrant induction of posterior *Hox* genes, which was rescued by knockdown of *let-7*-family microRNAs. These results suggest the involvement of the *Lin28*/*let-7* pathway in the modulation of the '*Hox* code' in vertebrates.

Results {#s2}
=======

*Lin28a*^--/--^ mice exhibit skeletal patterning defects {#s2-1}
--------------------------------------------------------

*Lin28a* exhibits unique spatiotemporal expression changes during early development ([Figure 1A](#fig1){ref-type="fig"}; [@bib106]; [@bib108]; [@bib109]). At E9.5, *Lin28a* is expressed ubiquitously; and subsequently, its expression disappears from head to tail at around E10.5 and E11.5 ([@bib108]; [@bib109]). To examine the potential significance of these dynamic expression changes and of the developmental function of *Lin28a* in mice, we generated *Lin28a*^--/--^ mice ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The normal Mendelian ratio of genotypes was observed for *Lin28a*^--/--^ mice during early to mid embryogenesis. However, the frequency of *Lin28a*^--/--^ mice decreased from E17.5 and after birth. Most of the *Lin28a*^--/--^ mice died perinatally or within a few days after birth ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). *Lin28a*^--/--^ mice exhibited short stature compared with wild-type (Wt) mice and showed severe growth defects ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). These findings are consistent with previous reports that *Lin28a* is necessary for normal growth ([@bib81]); however, our *Lin28a*^--/--^ mice showed severe phenotypes that might have been caused by differences in gene targeting construct and genetic background.

![Skeletal patterning defects in *Lin28a*^-/-^ mice.\
(**A**) Whole-mount in situ hybridization of *Lin28a* in E9.5--11.5 embryos. (**B**) Lateral views of Wt (left panel) and *Lin28a*^--/--^ mice (right panel) at E16.5. White arrow, the tip of the tail; white arrowhead, forelimb position; asterisk, hindlimb position. (**C**) Whole-mount in situ hybridization of *Myog* and *FGF8* in E10.5 embryos. The numbers indicate the expression domains of *Myog*. White arrowhead, the starting position of the hindlimb bud; black arrowhead, the ending position of the hindlimb bud. (**D--H**) Representative skeletal preparations of Wt (left panels) and *Lin28a*^--/--^ mice (right panels). Abbreviations/marks are described below. Lateral views of cervical and upper thoracic vertebrae (**D**); anterior views of the atlas and the axis (**E**); ventral views of the ribcage (**F**); dorsal views of thoracic vertebrae and ribs (**G**); and dorsal views of lumbar and sacral vertebrae (**H**) are shown. (**I**) Schematic diagram of skeletal phenotypes in *Lin28a*^-/-^ mice. Each abbreviation in (**D--I**) indicates as follows: C1--C7, 1^st^ to 7^th^ cervical vertebrae; T1-T13, 1^st^ and 13^th^ thoracic vertebrae; R1--R13, 1^st^ to 13^th^ ribs; L1--L6, 1^st^ to 6^th^ lumbar vertebrae; S1--S4, 1^st^ to 4^th^ sacral vertebrae; Ca1, 1^st^ caudal vertebrae. Black arrows in (**D--E**) indicate anterior arch of the atlas. Asterisks in (**F--I**) indicate the sites where skeletal deformations occurred.](elife-53608-fig1){#fig1}

We then examined anteroposterior axis formation in *Lin28a*^--/--^ mice since *Lin28a*^--/--^ mice showed a slight anterior shift of the hindlimbs and shortened tails ([Figure 1B](#fig1){ref-type="fig"}). To define the details of these phenotypes, whole-mount in situ hybridization of *Myog* and *Fgf8* was performed to outline somites and limb buds. The hindlimbs of *Lin28a*^--/--^ mice shifted anteriorly by one somite (from the 23^rd^ to the 28^th^ expression domains of *Myog*), whereas the position of the forelimb buds of *Lin28a*^--/--^ mice were not altered ([Figure 1C](#fig1){ref-type="fig"}). These results are supported by previous reports that tail bud-specific overexpression or knockout of Lin28a affects the number of caudal vertebrae ([@bib1]; [@bib78]).

To analyze the potential functions of *Lin28a* in skeletal patterning, Alcian blue and Alizarin red S staining were applied to the skeletal preparations. Although bone and cartilage development was normal, skeletal patterning defects were observed in *Lin28a*^--/--^ mice ([Figure 1D--H](#fig1){ref-type="fig"}). In *Lin28a*^--/--^ mice, the anterior arch of the atlas was formed from the second cervical vertebra (C2) ([Figure 1D](#fig1){ref-type="fig"}), and not from C1, as normally observed, or from the fusion of C1 and C2 ([Figure 1E](#fig1){ref-type="fig"}). These transformations were observed in 64.3% of *Lin28a*^--/--^ mice and in 21.1% of *Lin28a*^+/--^ mice; in contrast, they were never found in Wt mice ([Table 1](#table1){ref-type="table"}). There were only six pairs of true ribs attached to the sternum in *Lin28a*^--/--^ mice, whereas Wt and *Lin28a*^+/--^ mice had seven pairs ([Figure 1F](#fig1){ref-type="fig"}). Furthermore, an abnormal number of ribs was observed in *Lin28a*^--/--^ mice at 100% penetrance, whereas Wt and *Lin28a*^+/--^ mice exhibited the normal 13 pairs of ribs ([Figure 1G](#fig1){ref-type="fig"} and [Table 1](#table1){ref-type="table"}). These results suggest that posterior transformations of vertebral identity occur in the 7^th^ and 13^th^ thoracic vertebrae during skeletal patterning. Moreover, partial transformations were observed in the first sacral vertebra (S1), producing a morphological feature of lumbar vertebrae on only one side ([Figure 1H](#fig1){ref-type="fig"}). The frequency of these observations was significantly higher in *Lin28a*^--/--^ mice ([Table 1](#table1){ref-type="table"}). Finally, *Lin28a*^--/--^ mice showed various skeletal transformations ([Figure 1I](#fig1){ref-type="fig"}), suggesting that *Lin28a* plays a critical role in the specification of vertebrae along the anteroposterior axis.

###### Summary of skeletal abnormalities in *Lin28a* mutant mice.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  \                     Anterior arch of the atlas^\*^   Ribs†       Sternum attachment‡   Lumbar^§^                                        
  --------------------- -------------------------------- ----------- --------------------- ----------- ----------- ----------- ------------ -----------
  Wt(n = 16)            0                                16 (100%)   0                     16 (100%)   0           7 (43.8%)   8 (50%)      1 (6.2%)

  Lin28a^+/-^(n = 19)   4 (21.1%)                        19 (100%)   0                     19 (100%)   0           0           18 (94.7%)   1 (5.3%)

  Lin28a^-/-^\          9 (64.3%)                        0           14 (100%)             0           14 (100%)   0           9 (64.3%)    5 (35.7%)
  (n = 14)                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------

The percentages of each phenotype are shown in parenthesis.

\* The anterior arch of the atlas was formed from C2 or via fusion.

† Total number of pairs of ribs.

‡ Total number of pairs of true ribs that were attached to the sternum.

§ Total number of lumbar vertebrae. L6/S1\* indicates an abnormal sacral vertebra that had morphological features of a lumbar vertebra on only one side.

*Hox* genes are dysregulated in *Lin28a*^--/--^ mice {#s2-2}
----------------------------------------------------

The morphologies and characteristics of each vertebra are specified by the spatiotemporal expression of *Hox* genes ([@bib97]). It was remarkable that *Lin28a*^--/--^ mice exhibited global transformations with high penetration, whereas mutants of *Hox* genes showed abnormalities in a limited region of vertebrae. To test if *Hox* genes are involved in the phenotypes found in *Lin28a*^--/--^ mice, we examined *Hox* gene expression during embryogenesis. Quantitative real-time polymerase chain reaction (q-PCR) analyses of *Hox* genes were performed at E9.5, a time at which *Lin28a* was ubiquitously expressed in Wt mice ([Figure 1A](#fig1){ref-type="fig"}). *Lin28a*^--/--^ mice exhibited global dysregulation of *Hox* genes, which was most remarkable for the 5' (posterior) *Hox* genes ([Figure 2A](#fig2){ref-type="fig"}). Whole-mount in situ hybridization analyses revealed that the expression domain of *Hoxc13* and *Hoxd12* was enlarged anteriorly ([Figure 2B and C](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In contrast, there were no significant changes in the expression domain of the other *Hox* genes upregulated in *Lin28a*^--/--^ mice (Hoxa3, d3, b8, c8, a11, and a13) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These results suggest that the short-tailed phenotype in *Lin28a*^--/--^ mice might be caused by the anteriorization of *Hox* paralogous group 12 and 13 expression.

![*Hox* gene dysregulation in *Lin28a*^-/-^ mice.\
(**A**) q-PCR analyses of all *Hox* genes. All data are expressed as the mean ± standard error of the mean (SEM) (n = 3). \*p\<0.05. (**B**) Whole-mount in situ hybridization of *Hox* genes in E11.5 embryos. Lateral views (top panels) and dorsal views (bottom panels) of hindlimb and tail region are shown. Black arrowhead, anterior domain of *Hox* gene; HL, hindlimb; dashed line, hindlimb position; two-way arrow, distance from the hindlimb to the anterior domain of *Hoxc13*. (**C**) Histological analysis of E12.5 animals. Alcian blue staining (top panels) and in situ hybridization of *Hoxc13* (bottom panels) are shown. (**D**) Skeletal preparations of Wt (left panel) and *Lin28a*^+/--^ mice (right panel) that received RA treatment. R1--R13, 1^st^ to 13^th^ ribs; asterisk, the ablation of the 13^th^ rib. See also [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}. (**E**) Summary of *Hox* gene dysregulation in *Lin28a* mutants.\
Figure 2---source data 1.Source data related to panel (A).](elife-53608-fig2){#fig2}

We next focused on the skeletal patterning defects from the cervical to sacral region. It is known that Hox genes are modulated by retinoic acid (RA) signaling, and that RA exposure causes posterior transformations of vertebrae via global anteriorization of *Hox* gene expression ([@bib47]). Since Hox genes were dysregulated in *Lin28a*^-/-^ embryos, we hypothesized that the patterning defects of vertebrae observed in *Lin28a*^--/--^ mice are caused by the perturbation of *Hox* gene expression. To test this, we investigated the effects of perturbation of Hox gene expression by RA on skeletal pattern formation in Lin28a mutants. RA was injected intraperitoneally at 7.5 days postcoitum (dpc) and the skeletal patterning of each fetus was analyzed. We found that *Lin28a* mutant embryos showed RA sensitivity. *Lin28a*^+/--^ mice that received RA treatment showed loss of the 13^th^ pair of ribs, which coincided with the findings observed in *Lin28a*^--/--^ mice, whereas no obvious defects were observed in Wt littermates ([Figure 2D](#fig2){ref-type="fig"}). In contrast, no additional defects in the thoracic region were observed in the *Lin28a*^--/--^ embryos that natively had only 12 pairs of ribs ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). In the cervical region, the severity of skeletal patterning defects correlated with the genotype of *Lin28a* ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}--2F). After RA treatment, some *Lin28a*^+/--^ embryos exhibited the C1/C2 fusion phenotype ([Figure 2---figure supplement 2D](#fig2s2){ref-type="fig"}), whereas *Lin28a*^--/--^ embryos showed more severe defects that were characterized by fusion of the exoccipital bone with C1 and C2 ([Figure 2---figure supplement 2E and F](#fig2s2){ref-type="fig"}). These results show that perturbation of Hox genes by RA administration enhances the *Lin28a*^+/-^ and ^-/-^ phenotypes. In particular, since RA administration in *Lin28a*^+/-^ mice results in the same phenotype as untreated *Lin28a*^-/-^, it is possible that dysregulation of *Hox* genes is responsible for the skeletal patterning defects in *Lin28a*^--/--^ mice ([Figure 2E](#fig2){ref-type="fig"}).

*Lin28a* regulates *Cbx2* expression via *let-7* repression {#s2-3}
-----------------------------------------------------------

We examined the molecular mechanism underlying the *Lin28a-*mediated regulation of *Hox* gene expression during embryogenesis. Since *Lin28a* is known as a negative regulator of *let-7* biogenesis by interfering with Drosha processing of pri-let-7 ([@bib68]; [@bib94]), and by TUT4-mediated terminal uridylation and inhibition of Dicer processing ([@bib33]; [@bib6]), we examined the microRNA expression profile of *Lin28a*^--/--^ mice. TaqMan microRNA array analyses were performed on E9.5 embryos. Consistent with previous reports ([@bib94]; [@bib79]), we found that mature microRNAs of *let-7*-family members were significantly accumulated in *Lin28a*^--/--^ mice ([Figure 3A](#fig3){ref-type="fig"}). These results were also confirmed by q-PCR analysis of *let-7*-family members ([Figure 3B](#fig3){ref-type="fig"}). There was no difference between Wt and *Lin28a*^--/--^ mice with regards to the expression of either *mir-10* and *mir-196* family microRNAs, which are regulators of the spatial expression of *Hox* genes and of vertebral specification ([@bib102]; [@bib107]; [@bib37]; [Figure 3C](#fig3){ref-type="fig"}). Consistent with previous reports ([@bib33]; [@bib6]), these results imply that the ablation of Lin28a promotes the specific accumulation of *let-7* family microRNAs during embryogenesis.

![*Let-7* targets the polycomb gene directly.\
(**A**) Comparison of microRNA expression in Wt and *Lin28a*^--/--^ embryos at E9.5. (**B, C**) q-PCR analyses of *let-7*-family members (**B**) and *Hox*-embedded microRNAs (**C**). In (**B**), data are expressed as the mean (n = 3), and the relative amount of total *let-7* microRNAs is shown. (**D**) *let-7* target search with TargetScan and Phenotype Browser. (**E**) The *let-7* target site in the 3'UTR sequence of candidate genes. The *let-7* seed-matched sequence and mutated sequence are shown in red and blue, respectively. (**F**) Luciferase reporter activity in the presence/absence of the *let-7* target site in 3'UTR sequence. (**G--H**) qPCR and western blot analyses of candidate genes. (**I**) Dorsal views of thoracic vertebrae and ribs. Single heterozygous mutants (left and middle panels) and a double heterozygous mutant (right panel) are shown. R1--R13, 1^st^ to 13th ribs; asterisk, the ablation or truncation of the 13^th^ rib. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. (**J**) Frequency of rib defects in mutant mice. All data are expressed as the mean ± SEM (n = 3). \*p\<0.05. n.s., not significant.\
Figure 3---source data 1.Source data related to panel A-C, and F-H.](elife-53608-fig3){#fig3}

We then sought a potential target gene for *let-7*, which may be involved in the skeletal transformations observed in *Lin28a*^--/--^ mice. We performed comprehensive screening for the *let-7* target candidate genes using the following criteria; 1) *let-7* target genes, computationally predicted using TargetScan (856 genes), and 2) annotated genes responsible for posterior transformations and of which knockout mice show vertebrae that are similar to those observed in *Lin28a*^-/-^ mice, as screened by Mouse Genome Informatics (115 genes). We found that five of the genes (*Arl4d*, *Cbx2*, *Cbx5*, *Dusp4*, and *E2f6*) satisfied both criteria ([Figure 3D](#fig3){ref-type="fig"}). *Arl4d* and *E2f6* have been identified as potential *let-7* target genes ([@bib44]; [@bib56]), suggesting that this screening successfully extracted candidate genes. Three of the five genes (*Cbx2*, *Cbx5*, and *E2f6*) are PcG genes or *Polycomb*-associated genes ([@bib14]; [@bib69]; [@bib15]), suggesting that *Cbx5* and *E2f6*, as well as *Cbx2*, might be involved in *Hox* gene dysregulation via histone modifications and chromatin structural changes in *Lin28a*^-/-^ mice. Based on this screening, we examined if those five genes are true targets of *let-7* by Luciferase assay. We generated reporter constructs of luciferase-*let-7* target site-mutated 3'UTR sequence of each gene, and quantified *let-7*-dependent reporter activity in comparison with a Luciferase-wild type 3'UTR sequence construct ([Figure 3E](#fig3){ref-type="fig"}). We found that three of the five genes, *Cbx2*, *Cbx5,* and *E2f6*, were down-regulated in a *let-7*-dependent manner, whereas this down-regulation effect was not observed in the *let-7* target site mutated construct. In contrast, the potential let-7 target sequence of *Arl4d* and *Dusp4* did not affect the expression of luciferase. While these results in HEK293T cells with partial 3'UTR sequences do not completely exclude the possibility that *Dusp4* and *Arl4d* are not target genes of let-7, they do suggest that *Cbx2*, *Cbx5* and *E2f6* are direct targets of *let-7* ([Figure 3F](#fig3){ref-type="fig"}).

To confirm that these genes are affected by the *Lin28*/*let-7* axis in vivo, we performed mRNA and protein expression analyses on somite and neural tubes. qPCR analyses showed that *Arl4d* was significantly downregulated in *Lin28a*^-/-^ embryos ([Figure 3G](#fig3){ref-type="fig"}). However, the luciferase assay revealed that luciferase expression was not affected by a let-7 target site mutation in the Ard4 3\' UTR sequence, suggesting that *Arl4d* is not a direct target of *let-7*. Protein expression analyses revealed that *Cbx2* was the only gene that was significantly downregulated in *Lin28a*^-/-^ embryos, and also its expression was affected in a *let-7*-dependent manner ([Figure 3F and H](#fig3){ref-type="fig"}). These findings suggest that *Cbx2* is, at least in part, a molecular target of the *Lin28a*/*let-7* pathway in skeletal patterning.

*Cbx2* is one of the PcG genes that regulates *Hox* genes via histone modification, and ablation of Cbx2 shows skeletal patterning defects in mice ([@bib14]; [@bib69]; [@bib15]). We considered that decreased expression of Cbx2 might cause the abnormal skeletal formation found in *Lin28a*^-/-^ mice. Therefore, we examined whether decreasing the expression level of Cbx2 in Lin28a+/-could induce a similar phenotype as *Lin28a*^-/-^ mice. We generated *Cbx2* mutant mice using CRISPR/Cas9 and interbred the *Cbx2* mutant with *Lin28a*^+/--^ mice ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The *Cbx2* homozygous mutants exhibited skeletal patterning defects ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}--1E): fusion of C1 and C2 vertebrae, additional rib formation from the 7^th^ cervical vertebra, T1 to T2 transformation of the spinous process, and 13^th^ rib truncation. Similar observations were reported for Cbx2-null mice ([@bib14]; [@bib46]). We generated double heterozygous mutants of *Lin28a* and *Cbx2* (*Lin28a*^+/--^; *Cbx2*^+/--^) and analyzed their skeletal patterning. The double heterozygous mice showed ablation or truncation of the 13^th^ pair of ribs, although the *Lin28*^+/--^ and *Cbx2*^+/--^ single mutants did not show any obvious phenotypic irregularities ([Figure 3I and J](#fig3){ref-type="fig"}). These results show that decreased expression of Cbx2 enhances the *Lin28a*^+/-^ phenotypes. In particular, since *Lin28a*^+/-^;Cbx2^+/-^ double mutant mice showed the deformation of the 13^th^ pair of ribs, which was similar to the phenotype observed in *Lin28a*^-/-^ mice, it was possible that dysregulation of *Cbx2* is responsible for the phenotype of *Lin28a*^--/--^ mice. Together, these results indicate that *let-7* directly regulates *Cbx2,* and that genetic interactions exist between *Lin28a* and *Cbx2*. Furthermore, they suggest that *Lin28a*/*let-7* reciprocal feedback regulates Cbx2 expression, and that this pathway contributes to the regulation of proper skeletal patterning during embryogenesis.

The *Lin28a*/*let-7* pathway modulates PRC1 occupancy at posterior *Hox* loci {#s2-4}
-----------------------------------------------------------------------------

*Hox* gene expression is epigenetically restricted to unique spatiotemporal patterns during embryogenesis by PcG genes ([@bib85]). To determine if the *Lin28a*/*let-7*/*Cbx2* axis regulates skeletal patterning via *Hox* gene expression, we analyzed histone modifications and PcG occupancy at the *Hox* loci. We performed chromatin immunoprecipitation (ChIP) and q-PCR analyses on E9.5 somites and neural tubes ([Figure 4A](#fig4){ref-type="fig"}). For each assay, ChIP was performed on a pool of dissected somites and neural tubes from ten embryos (as n = 1). First of all, we analyzed the repressive histone modification (H3K27me3) at *Hoxa* cluster loci of Wt. We found the promoter regions of *Hoxa3*, *Hoxa9*, *Hoxa10*, *Hoxa11*, and *Hoxa13* exhibited a high concentration of histone H3K27me3 ([Figure 4B](#fig4){ref-type="fig"}). Intriguingly, the same genes were upregulated in *Lin28a*^--/--^ mice ([Figure 2A](#fig2){ref-type="fig"}), suggesting that these genes are tightly regulated epigenetically and that the loss of repressive histone modifications leads to the upregulation of these *Hox* genes.

![Histone modifications and polycomb occupancy at *Hox* loci in *Lin28a*^-/-^ mice.\
(**A**) Schematic diagram of the experimental procedure for ChIP analysis. (**B**) ChIP and q-PCR analyses of H2K27me3 in *Hox* A cluster genes in Wt embryos. (**C--G**) ChIP and q-PCR analyses of H3K27me3 (**C**), H3K4me3 (**D**), Cbx2 (**E**), Ring1b (**F**), and H2AK119ub (**G**). Percentages of immunoprecipitated DNA compared with the input are shown. (**H**) Summary of the chromatin state of *Hox* loci in Wt and *Lin28a*^--/--^ embryos. All data are expressed as the mean ± SEM (n = 3). \*p\<0.05. n.s., not significant.\
Figure 4---source data 1.Source data related to panel B-G.](elife-53608-fig4){#fig4}

Based on the analysis of phenotype of the *Lin28a*^--/--^ skeletal transformation ([Figure 1B--I](#fig1){ref-type="fig"}) and *Hox* cluster gene expression pattern of *Lin28a*^--/--^ embryos ([Figure 2A--C](#fig2){ref-type="fig"}), we focused on *Hoxa3* and *Hoxd3*, which are involved in C1-C2 malformation and partial fusion in knockout mice ([@bib13]). In addition, we focused on *Hoxa11*, which has been reported as the responsible gene for T13 to L1 skeletal transformation in mutated mice ([@bib83]), *Hoxd12* and *Hox*c*13*, which were upregulated in *Lin28a*^--/--^ embryos, and *Hoxa1* as a representative of the anterior *Hox* genes ([Figure 4C--G](#fig4){ref-type="fig"}). Subsequently, we performed ChIP and q-PCR analyses using anti-H3K27me3 and anti-H3K4me3 antibodies in Wt and *Lin28a*^--/--^ embryos ([Figure 4C and D](#fig4){ref-type="fig"}). We found that for histone H3 modifications, both K27me4 and K4me3 were not altered in *Lin28a*^--/--^ embryos compared with Wt ([Figure 4C and D](#fig4){ref-type="fig"}). We also performed ChIP using antibodies against PRC1 components to test their occupancy at *Hox* loci ([Figure 4E and F](#fig4){ref-type="fig"}). Consistent with the expression level of Cbx2 ([Figure 3G](#fig3){ref-type="fig"}), we found at least a two-fold reduction of its binding at posterior *Hox* regions in *Lin28a*^--/--^ mice ([Figure 4E](#fig4){ref-type="fig"}). Intriguingly, the occupancy of Ring1b, another component of PRC1 ([@bib88]), and H2AK119 ubiquitination (H2AK119ub) which is catalyzed by Ring1b ([@bib88]), were also reduced in *Lin28a*^--/--^ mice ([Figure 4F--G](#fig4){ref-type="fig"}). Because each posterior *Hox* gene (*Hoxa11*, *Hoxc13*, and *Hoxd12*) is located on distinct chromosomes, these results indicate a critical role for the *Lin28a*/*let-7* axis in PcG-mediated *Hox* gene repression. Taken together, these findings suggest that Cbx2 repression by *let-7* leads to the reduction of PRC1 occupancy at the *Hox* loci and the transcriptional initiation of posterior *Hox* genes ([Figure 4H](#fig4){ref-type="fig"}).

*Let-7* knockdown rescues *Hox* gene dysregulation in *Lin28a*^--/--^ cells {#s2-5}
---------------------------------------------------------------------------

To further elucidate the importance of the direct regulation of *let-7* by Lin28a during *Hox* gene regulation, we tested whether *Hox* gene dysregulation could be rescued by knockdown of *let-7*-family microRNAs. To accomplish this, *Lin28a*^--/--^embryonic stem (ES)-like cells were established from mutant blastocysts. Each *Lin28a*^--/--^ clone resembled Wt cells ([Figure 5A](#fig5){ref-type="fig"}), and we confirmed that the Lin28a protein was not detected in *Lin28a*^--/--^ ES cells ([Figure 5B](#fig5){ref-type="fig"}). These colonies showed high alkaline phosphatase activity ([Figure 5A](#fig5){ref-type="fig"}) and also expressed pluripotent factors ([Figure 5C](#fig5){ref-type="fig"}). As observed in *Lin28a*^--/--^ embryos ([Figure 3B](#fig3){ref-type="fig"}), global accumulation of *let-7*-family microRNAs was observed in the mutant cells ([Figure 5D](#fig5){ref-type="fig"}).

![Knockdown of *let-7* can reverse *Hox* gene dysregulation.\
(**A**) Morphology (top panels) and alkaline phosphatase activity (bottom panels) of Wt and *Lin28a*^--/--^ ES-like cells. (**B**) Western blot analysis of Lin28a in ES-like cells. β-actin is shown as a loading control. (**C**) q-PCR analysis of stemness factors. (**D**) q-PCR analysis of *let-7*-family members. The level of expression relative to total let-7 amount in Wt is shown. (**E**) q-PCR analyses of *Hoxa11* and *Hoxd12* over a time course of 3, 6, 9, 12 days following embryoid body formation. (**F**) Precursor sequences of *let-7*-family members and guide RNAs for *let-7* targeting Let-7 mature microRNAs are shown in red. The protospacer adjacent motif (PAM) sequence for hCas9 is highlighted in yellow, and targeting sequences are underlined. (**G**) *Let-7* expression in Wt, *Lin28a*^--/--^ and *Lin28a*^--/--^; *let-7* KD cells. The level of expression relative to total let-7 amount in Wt is shown. (**H**) *Let-7* knockdown rescues *Hox* gene dysregulation in *Lin28a*^--/--^ cells. (**I**) Cbx2 expression level of Wt, *Lin28a*^--/--^ and *Lin28a*^--/--^; *let-7* KD derived EBs. β-actin is shown as a loading control. (**J**) Schematic diagram of *let-7* target site deletion from *Cbx2* 3'UTR and genotyping via PCR of mutant clones. (**K**) q-PCR analyses of *Hoxa11* and *Hoxd12* following embryoid body formation. (**L**) Schematic diagram of *Lin28a*/*let-7* mediated *Hox* gene regulation. All data are expressed as the mean ± SEM (n = 3). n.s., not significant.\
Figure 5---source data 1.Source data related to panel C-E, G-H, and K.](elife-53608-fig5){#fig5}

In the following experiments, we differentiated ES cells to embryoid bodies. ES cells and embryoid bodies require different PRC1 components to maintain their state. ES cells are maintained in an undifferentiated state, using Cbx7 containing PRC1. On the other hand, when ES cells exit the pluripotent state and differentiate into embryoid bodies, Cbx2 is expressed and becomes a component of PRC1 ([@bib65]). Thus, we utilized embryoid bodies as an appropriate model to analyze *Hox* genes via *Lin28*/*Let-7*/*Cbx2* axis. Embryoid bodies were produced from each clone and expression changes of *Hox* genes were analyzed. *Hox* genes were upregulated upon differentiation in these embryoid bodies, suggesting that a recapitulation of the *Hox* gene upregulation observed in *Lin28a*^--/--^ mice occurred in *Lin28a*^--/--^ ES-like cells ([Figure 5E](#fig5){ref-type="fig"}).

Next, we knocked down the *let-7* family in *Lin28a*^--/--^ ES-like cells using the CRISPR/Cas9 system to test if *Hox* gene upregulation could be rescued by the reduction of *let-7* microRNAs. The major *let-7* family is composed of 11 genes (*a-1*, *a-2*, *b*, *c-1*, *c-2*, *d*, *e*, *f-1*, *f-2*, *g*, and *i*), and we performed the knockdown of this series of *let-7* genes using guide RNAs targeting *let-7s* ([Figure 5F](#fig5){ref-type="fig"}). The clone that yielded a highly efficient deletion of *let-7* microRNAs in *Lin28a*^--/--^ cells (*Lin28a*^--/--^; *let-7*KD) was selected for further analyses. We confirmed the accumulation of *let-7* in *Lin28a*^--/--^ cells and the drastic reduction in *Lin28a*^--/--^; *let-7*KD clones ([Figure 5G](#fig5){ref-type="fig"}). qPCR analysis revealed that dysregulation of Hoxa11 and Hoxd12 was rescued in *Lin28a*^--/--^; *let-7*KD clones ([Figure 5H](#fig5){ref-type="fig"}). Moreover, we also confirmed that a decreasing Cbx2 protein expression level in embryoid bodies-derived *Lin28a*^--/--^ ES-like cells was rescued by knock down of *let-7* ([Figure 5I](#fig5){ref-type="fig"}).

To directly prove that the *Lin28a*^--/--^ phenotype results from the *let-7*-mediated down-regulation of *Cbx2*, we established *Lin28a*^-/-^ ES cells with *let-7* target site deletion from *Cbx2* 3'UTR (*Lin28a*^--/--^; *Cbx2* 3'UTR mutant) using CRISPR/Cas9 system, and examined whether *let-7* target site deletion from *Cbx2* 3'UTR could rescue *Hox* gene dysregulation. Two guide RNAs targeting the *let-7* binding site in *Cbx2* 3'UTR were constructed and transfected with the Cas9 expression vector into *Lin28a*^--/--^ ES-like cells for the establishment of *Cbx2* 3'UTR mutant cell lines ([Figure 5J](#fig5){ref-type="fig"}). Furthermore, we generated embryoid bodies from Wt, *Lin28a*^--/--^, and *Lin28a*^--/--^; *Cbx2* 3'UTR mutant clones in the same manner as that of the *let-7* knock down experiment ([Figure 5G--I](#fig5){ref-type="fig"}), and the expression level of *Hox* genes were analyzed. Consistent with the result of *let-7* knock down ([Figure 5G--I](#fig5){ref-type="fig"}), we found that *Hoxa11* and *Hoxd12* were up-regulated in *Lin28a*^--/--^ cells, and that this abnormal expression was absent in *Lin28a*^--/--^; *Cbx2* 3'UTR mutant cells ([Figure 5K](#fig5){ref-type="fig"}). These results suggest that *let-7*-mediated Cbx2 repression is, at least in part, responsible for *Hox* gene dysregulation in Lin28a^--/--^ mice. Taken together, our results suggest that the upregulation of *let-7* leads to decreased PRC1 occupancy, which causes the disruption of the '*Hox* code,' thus indicating the potential role of the *Lin28a*/*let-7* pathway in skeletal patterning via *Polycomb*-mediated *Hox* gene regulation ([Figure 5L](#fig5){ref-type="fig"}).

Discussion {#s3}
==========

The body plan along the anteroposterior axis is tightly regulated by *Hox* genes. During development, each *Hox* gene must be activated at a precise position with precise timing. Spatiotemporal regulation via chromatin conformational changes is essential for *Hox* gene expression and for subsequent anteroposterior patterning ([@bib84]); however, the molecular mechanisms behind these processes are not fully understood. In this study, we demonstrated the fundamental role of the *Lin28a*/*let-7* pathway in skeletal patterning and vertebral specification. *Lin28a*-mediated repression of *let-7* biogenesis is required for *Cbx2* expression and *Hox* gene repression by PcG genes. It is known that the deletion mutants of the *Hox* early enhancer exhibit anterior transformations of vertebrae because of the heterochrony of *Hox* gene expression ([@bib45]). In our *Lin28a*^--/--^ mice, posterior transformations were observed in the thoracic region ([Figure 1D--I](#fig1){ref-type="fig"}), suggesting that developmental timing of *Hox* gene initiation occurs earlier than in Wt mice. Consistent with this speculation, precocious expression of *Hoxc13* causes premature arrest of axial extension, similar to that of *Lin28a*^--/--^ mice ([@bib110]; [@bib59]). This indicates that the tail truncation observed in *Lin28a*^--/--^ mice might be caused by spatiotemporal dysregulation of *Hoxc13* ([Figure 2B and C](#fig2){ref-type="fig"}). Recently, two independent groups reported the function of the Lin28 family as regulators of trunk elongation ([@bib1]; [@bib78]). Tail bud specific overexpression of the *Lin28* family increased caudal vertebrae number ([@bib1]; [@bib78]). Moreover, the loss of *Lin28* in the tail bud resulted in the reduction of caudal vertebrae number ([@bib78]). These results are consistent with our *Lin28a* ^-/-^ mice phenotypes with short stature and shortened tails ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Furthermore, [@bib1] showed that Lin28 and Hox13 had opposite functions in tail bud proliferation, suggesting that the balance of the expression of those two genes, which might be regulated by GDF signaling, is one of the determinants of tail length. Our results revealed the epigenetic inhibition of HoxPG13 by the *Lin28a*/*let-7*/*Cbx2* pathway, which might be one of the mechanisms that explains the antagonistic function of Lin28a and HoxPG13 in axial elongation as well as in skeletal patterning.

In contrast to the short tailed-phenotype caused by HoxPG13 inhibition, the molecular mechanisms underlying the other skeletal patterning defects found in the cervical, thoracic, and lumbosacral regions were still unknown. Aires et al. and Robinton et al. showed that Lin28a regulated the cell fate choice between mesodermal cells and neural cells; however, no skeletal transformations were observed in their *Lin28a* mutant mice ([@bib1]; [@bib78]). Further analyses are required to determine if the skeletal patterning defects found in the cervical, thoracic, and lumbosacral regions of *Lin28a*^-/-^ mice are caused by the dysregulation of cell fate choice. Based on the analysis of phenotype of the *Lin28a*^--/--^ skeletal transformations ([Figure 1B--I](#fig1){ref-type="fig"}), we focused on *Hoxa3*/*d3* for the C1-C2 malformation and partial fusion ([@bib13]), *Hoxb8/c8* for rib patterning ([@bib91]), and *Hoxa11* for T13 to L1 skeletal transformation ([@bib83]). However, these *Hox* genes showed no obvious difference in their expression patterns, although the expression of the genes was up-regulated ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Skeletal transformations are mainly caused by the altered expression pattern of *Hox* genes. However, it is also possible that changes in the expression amount of Hox genes may be involved in skeletal patterning. For instance, *Dll1* enhancer-driven *Hoxb6* transgenic mice show ectopic rib-like structures in the cervical, lumber, sacral and caudal regions. However, malformation of the axial skeleton was shown even in the thorax, which is the regular expressing region of *Hoxb6* ([@bib93]). These results suggest that the *Hox*-code of this specific region might have been edited due to the elevated expression of a specific *Hox* gene, which might cause the morphological change of vertebrae in our *Lin28a*^--/--^ mice.

PcG genes are regulators of the '*Hox* code' at the level of chromatin structure, which occurs via epigenetic histone modifications ([@bib60]; [@bib84]). In ES cells, *Hox* genes are silenced in a bivalent state containing both H3K27me3, a repressive, and H3K4me3, an active histone marker. During development, the epigenetic status of *Hox* loci is dynamically balanced by PcG genes and *Trithorax* group (TrxG) genes, which are required for the trimethylation of H3K4. PcG genes should be repressed prior to the initiation of *Hox* gene expression to open the chromatin along the anteroposterior axis. However, the precise molecular mechanisms underlying the inhibition of the expression of PcG genes during embryogenesis are not fully understood. Here, we provide evidence that the *Lin28a*/*let-7* pathway is, at least in part, one of the mechanisms involved in the regulation of PcG genes ([Figure 3](#fig3){ref-type="fig"}). Cbx2 is required for the binding of PRC1 to target loci and recognition of H3K27me3, and these processes are catalyzed by Ezh2, the main component of PRC2. *Ezh2* is directly targeted by *let-7* microRNAs in primary fibroblasts and cancer cells ([@bib50]). In contrast with those findings, there were no apparent differences in the level of H3K27me3 at *Hox* loci in *Lin28a*^--/--^ mice ([Figure 4C](#fig4){ref-type="fig"}). *Ezh2*^--/--^ embryos died at the peri- and post-implantation stages ([@bib70]), whereas mutant mice of the PRC1 genes exhibited skeletal transformations ([@bib92]; [@bib2]; [@bib14]; [@bib88]; [@bib55]; [@bib46]) that were similar to those of *Lin28a*^--/--^ mice ([Figure 1D--I](#fig1){ref-type="fig"}). These observations suggest that the *Lin28a*/*let-7* pathway is involved in the later phases of epigenetic silencing of *Hox* genes during skeletal patterning. Since *Lin28a*^+/-^;Cbx2^+/-^ double mutant mice showed the deformation of the 13^th^ pair of ribs, which was similar to the phenotype observed in *Lin28a*^-/-^ mice, it was possible that dysregulation of *Cbx2* is responsible for the phenotype of *Lin28a*^--/--^ mice ([Figure 3I](#fig3){ref-type="fig"}). Moreover, we observed the reduction of PRC1 occupancy at *Hox* loci in *Lin28a*^--/--^ mice ([Figure 4E and F](#fig4){ref-type="fig"}). These findings indicate that *let-7*-mediated Cbx2 repression leads to the reduction of PRC1 occupancy at *Hox* loci, resulting in the transcriptional initiation of posterior *Hox* genes ([Figure 4H](#fig4){ref-type="fig"}).

In addition to epigenetic regulation by PcG genes, posttranscriptional regulation by microRNAs is also required for anteroposterior patterning. During mouse embryogenesis, mesoderm-specific ablation of Dicer, which is an RNase III enzyme that is required for microRNA biogenesis, results in a posterior shift in hindlimb position ([@bib111]), suggesting the involvement of microRNAs in normal skeletal patterning and vertebrae specification. Two microRNA families, *mir-10s* and *mir-196s*, are located in *Hox* clusters, and they are thought to regulate *Hox* gene expression and specify the regional identities along the anteroposterior axis ([@bib32]). It has also been reported that the *mir-17--92* cluster, which contains *mir-17*, *mir-18*, *mir-19*, *mir-20*, and *mir-92*, is required for normal skeletal patterning ([@bib29]). Although *Lin28a* is a regulator of let-7 microRNA biogenesis, the expression of these microRNAs was not altered in the *Lin28a*^--/--^ mice compared with Wt animals ([Figure 3A and C](#fig3){ref-type="fig"}). These results suggest that the *Lin28a/let-7* pathway acts independently of these microRNAs in *Hox* gene regulation. *Mir-10s* and *mir-196s* are involved in the spatial regulation of *Hox* genes to shut down target *Hox* genes in specific regions ([@bib32]), whereas *let-7* might be required for temporal activation of Hox genes via Lin28a downregulation during development. These results suggest that *let-7* can be distinguished from other microRNAs in skeletal patterning, and that the *Lin28a*/*let-7* pathway links posttranscriptional regulation to PcG-mediated epigenetic regulation in *Hox* gene regulation.

MicroRNAs are thought to regulate hundreds of target genes and to modulate multiple biological processes, and hence, the accumulation of *let-7* observed in *Lin28a*^--/--^ mice might lead to extensive disorders of gene regulatory networks. It is well known that the *let-7* family regulates *c-Myc*, *K-ras*, *Hmga2*, and other genes that are involved in cell proliferation and oncogenesis ([@bib62]; [@bib53]; [@bib43]; [@bib80]). Knockout mice for these genes exhibit dwarfism caused by a reduction of cell proliferation that is similar to that observed in *Lin28a*^--/--^ mice ([@bib112]; [@bib48]; [@bib42]; [@bib89]). These observations suggest that the growth defects and postnatal mortality of *Lin28a*^--/--^ mice ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) may be attributed to the dysregulation of such genes; however, their requirement for skeletal patterning has not been characterized. Despite the contribution of these genes to the *Lin28a*^--/--^ phenotype, it is noteworthy that there was a genetic interaction between *Lin28a* and *Cbx2* during skeletal patterning ([Figure 3I](#fig3){ref-type="fig"}). These results suggest that the *Lin28a*/*let-7*/*Cbx2* pathway is, at least in part, responsible for normal skeletal patterning. In addition to *Lin28a, Lin28b* regulates *let-7* biogenesis, and it is known that single nucleotide polymorphisms (SNPs) of the human *LIN28B* locus correlated with height and the timing of menarche ([@bib54]; [@bib74]; [@bib31]; [@bib71]; [@bib100]; [@bib87]). These studies suggest that the regulation of developmental timing by *Lin28b* is also conserved in mammals; however, its requirement in skeletal patterning is still unclear.

The expression level of Cbx2 was also downregulated in heterozygous *Lin28a*^+/-^ ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). This indicates that Lin28a expression in heterozygous *Lin28a*^+/-^ is reduced to less than half ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), suggesting that other target molecules regulated by Lin28a might be involved in this skeletal transformation phenotype. In addition to the regulation of *let-7*, it is also known that Lin28a and its homolog, Lin28b, bind to and modulate the translation efficiency of specific mRNAs, such as *Igf2*, *Oct4*, *Ccnb1*, *Cdk6*, *Hist1h2a*, and *Bmp4* ([@bib103]; [@bib57]; [@bib75]; [@bib104]). Moreover, recent HITS-CLIP and PAR-CLIP technology identified a variety of mRNAs as *Lin28* family targets ([@bib101]; [@bib58]; [@bib28]; [@bib11]). Among them, two studies showed that the *Lin28* family might have the potential to bind specific *Hox* genes in HEK293T, DLD1, and Lovo cell lines (Lin28a to *Hoxa9*, *a11*, *b4*, *b6*, *b9*, *c4*, *d11*; Lin28b to *Hoxa9*, *b3*, *b4*, *b7*, *b8*, *b9*, *d13*) ([@bib28]; [@bib58]), although CLIP-Seq analysis with ES cells did not show that ([@bib11]). Moreover, *Cbx5* is a *Lin28a* target gene as well as one of the potential *let-7* targets. *Cbx5* encodes a heterochromatin binding protein, and the depletion of this gene causes skeletal defects in mice, although the protein level of Cbx5 was not altered in *Lin28a*^--/--^ mice. These previous reports and our results imply that both *let-7*-dependent and -independent function of *Lin28a* might affect skeletal patterning during development. However, further studies are required to deepen the understanding of the developmental functions of *Lin28* family and its involvement in skeletal patterning.

Taken together, our results suggest that the negative feedback between *Lin28a* and *let-7* regulates the PRC1 component, *Cbx2,* and the subsequent spatiotemporal expression of *Hox* genes during mammalian embryogenesis. The loss of Lin28a caused skeletal transformations via the premature loss of PRC1 at the promoter region of posterior *Hox* genes, thus establishing a new role of the *Lin28a*/*let-7* pathway in the modulation of the '*Hox* code.' It is of interest to test whether this role of *Lin28a*/*let-7* in *Hox* regulation was acquired in the evolutional process, or if it has always been involved in heterochrony in *C. elegans*.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                            Source or\                       Identifiers                                                                                                                                                                                                                                                       Additional\
  (species) or resource                                                                 reference                                                                                                                                                                                                                                                                                          information
  ------------------------------ ------------------------------------------------------ -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Antibody                       anti-Arl4d                                             Santa Cruz                       SC-271274                                                                                                                                                                                                                                                         mouse monoclonal antibody, for western blot, at 1:500

  Antibody                       anti-b-actin                                           Sigma                            A5316                                                                                                                                                                                                                                                             mouse monoclonal antibody, for western blot, at 1:2000

  Antibody                       anti-Cbx2                                              Abcam                            ab80044                                                                                                                                                                                                                                                           Rabbit polyclonal antibody, for western blot, at 1:500

  Antibody                       anti-CBX2                                              Bethyl Laboratories              A302-524A                                                                                                                                                                                                                                                         Rabbit polyclonal antibody, for ChIP

  Antibody                       anti-Cbx5                                              Cell Signaling Technology        \#2616S                                                                                                                                                                                                                                                           Rabbit polyclonal antibody, for western blot, at 1:1000

  Antibody                       anti-DIG-AP Fab fragment antibody                      Roche                            1-093-274                                                                                                                                                                                                                                                         sheep polyclonal antibody, for in situ hybridization

  Antibody                       anti-Dusp4 (MKP-2)                                     Santa Cruz                       SC-1200                                                                                                                                                                                                                                                           Rabbit polyclonal antibody, for western blot, at 1:250

  Antibody                       anti-E2f6                                              Santa Cruz                       SC-8366                                                                                                                                                                                                                                                           goat polyclonal antibody, for western blot, at 1:500

  Antibody                       anti-Lin28a                                            Cell Signaling Technology        \#3978S                                                                                                                                                                                                                                                           Rabbit polyclonal antibody, for western blot, at 1:1000

  Antibody                       anti-mouse IgG HRP-conjugated                          Sigma                            A2304                                                                                                                                                                                                                                                             goat affinity isolated antibody, for western blot, at 1:2000

  Antibody                       anti-rabbit IgG HRP-conjugated                         Sigma                            A6154                                                                                                                                                                                                                                                             goat affinity isolated antibody, for western blot, at 1:2000

  Antibody                       anti-trimethyl-histone H3 (Lys27)                      Millipore                        \#07--449                                                                                                                                                                                                                                                         Rabbit Polyclonal Antibody, for ChIP

  Antibody                       anti-trimethyl-histone H3 (Lys4)                       Millipore                        \#07--473                                                                                                                                                                                                                                                         Rabbit Polyclonal Antibody,for ChIP

  Antibody                       normal rabbit IgG                                      Santa Cruz                       SC-2027                                                                                                                                                                                                                                                           Rabbit Polyclonal Antibody, for ChIP

  Antibody                       RING1B (D22F2) XP rabbit monoclonal antibody (mAb)     Cell Signaling Technology        \#5694S                                                                                                                                                                                                                                                           rabbit monoclonal antibody, for ChiP

  Cell Lines                     HEK293T cells                                          ATCC                             RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                                                                                                                                                                                                        

  Cell Lines                     Wt or Lin28a-/-ES like cells                           Materials and methods section    N/A                                                                                                                                                                                                                                                               

  Chemical compound, drug        2-mercaptoethanol                                      Gibco                            \#21985023                                                                                                                                                                                                                                                        

  Chemical compound, drug        acetic anhydride                                       Wako                             \#011--00276                                                                                                                                                                                                                                                      

  Chemical compound, drug        Alcian Blue                                            Sigma                            A5268-10G                                                                                                                                                                                                                                                         

  Chemical compound, drug        Alizarin Red S                                         Sigma                            A5533-25G                                                                                                                                                                                                                                                         

  Chemical compound, drug        Chaps                                                  Dojindo Molecular Technologies   349--04722                                                                                                                                                                                                                                                        

  Chemical compound, drug        CHIR 99021                                             Wako                             034--23103                                                                                                                                                                                                                                                        

  Chemical compound, drug        Fast Green FCF                                         Sigma                            F7258-25G                                                                                                                                                                                                                                                         

  Chemical compound, drug        Fast Red Violet LB Salt                                Sigma                            F3381-5G                                                                                                                                                                                                                                                          

  Chemical compound, drug        formamide                                              Sigma                            SIGF5786                                                                                                                                                                                                                                                          

  Chemical compound, drug        G-418 Sulfate                                          Wako                             074--05963                                                                                                                                                                                                                                                        

  Chemical compound, drug        glycine                                                Wako                             \#077--00735                                                                                                                                                                                                                                                      

  Chemical compound, drug        heparin                                                Nacalai Tesque                   17513--96                                                                                                                                                                                                                                                         

  Chemical compound, drug        NBT/BCIP                                               Roche                            \#1697471                                                                                                                                                                                                                                                         

  Chemical compound, drug        PD0325901                                              Wako                             162--25291                                                                                                                                                                                                                                                        

  Chemical compound, drug        PFA                                                    Wako                             \#162--16065                                                                                                                                                                                                                                                      

  Chemical compound, drug        Retinoic acid (all-trans)                              Wako                             182--01111                                                                                                                                                                                                                                                        

  Chemical compound, drug        sodium pyruvate                                        Gibco                            \#11360070                                                                                                                                                                                                                                                        

  Chemical compound, drug        triethanolamine                                        Wako                             142--05625                                                                                                                                                                                                                                                        

  Commercial assay, kit          Chemi-Lumi One                                         Nacalai Tesque                   \#07880                                                                                                                                                                                                                                                           

  Commercial assay, kit          DirectPCR Lysis reagent                                Viagen Biotech                   \#102 T                                                                                                                                                                                                                                                           

  Commercial assay, kit          ExoSAP-IT Express PCR Cleanup Reagents                 ThermoFisher scientific          \#75001                                                                                                                                                                                                                                                           

  Commercial assay, kit          FugeneHD                                               Promega                          E2312                                                                                                                                                                                                                                                             

  Commercial assay, kit          GoTaq Flexi DNA Polymerase                             Promega                          M8298                                                                                                                                                                                                                                                             

  Commercial assay, kit          Lipofectamine 2000                                     Invitrogen                       \#11668019                                                                                                                                                                                                                                                        

  Commercial assay, kit          MegaClear Transcription Clean-Up Kit                   Invitrogen                       AM1908                                                                                                                                                                                                                                                            

  Commercial assay, kit          mMESSAGE mMACHINE T7 Kit                               Invitrogen                       AM1344                                                                                                                                                                                                                                                            

  Commercial assay, kit          SuperSignal West Femto Maximum Sensitivity Substrate   Thermo Fisher Scientific         \#34095                                                                                                                                                                                                                                                           

  Commercial assay, kit          SYBR Green PCR Master Mix                              Applied Biosystems               \#4309155                                                                                                                                                                                                                                                         

  Commercial assay, kit          TaqMan MicroRNA Assays                                 Applied Biosystems               *let-7a (\#000377), let-7b (\#002619), let-7c (\#000379), let-7d (\#002283), let-7e (\#002406), let-7f (\#000382), let-7g (\#002282), let-7i (\#002221), mir-98 (\#000577), mir-10a (\#000387), mir-10b (\#002218), mir-196a (\#241070), mir-196b (\#002215),*\   
                                                                                                                         *RNU6B (\#001093)*                                                                                                                                                                                                                                                

  Commercial assay, kit          TaqMan Rodent MicroRNA Array A and B                   Applied Biosystems               \#4398979                                                                                                                                                                                                                                                         

  Commercial assay, kit          TaqMan Rodent MicroRNA Array B                         Applied Biosystems               \#4398980                                                                                                                                                                                                                                                         

  Commercial assay, kit          TaqMan Universal Master Mix II, no UNG                 Applied Biosystems               \#4440040                                                                                                                                                                                                                                                         

  Commercial assay, kit          the TaqMan MicroRNA Reverse Transcription kit          Applied Biosystems               \#4366597                                                                                                                                                                                                                                                         

  Peptide, recombinant protein   ESGRO Recombinant Mouse LIF Protein                    Merck Millipore                  ESG1107                                                                                                                                                                                                                                                           

  Peptide, recombinant protein   Proteinase K recombinant PCR Grade                     Roche                            03-115-887-001                                                                                                                                                                                                                                                    

  Strains                        Cbx2 deficient mice                                    Materials and methods section    N/A                                                                                                                                                                                                                                                               

  Strains                        Lin28a deficient mice                                  Materials and methods section    N/A                                                                                                                                                                                                                                                               

  Strains                        Meox2 Cre                                              The Jackson Laboratory           N/A                                                                                                                                                                                                                                                               

  Other                          Dulbecco's Modified Eagle's medium (DMEM)              Sigma                            D5796                                                                                                                                                                                                                                                             

  Other                          Glutamax                                               Gibco                            \#35050061                                                                                                                                                                                                                                                        

  Other                          Immobilon                                              Millipore                        WBKLS0100                                                                                                                                                                                                                                                         

  Other                          nonessential amino acids (NEAAs)                       Gibco                            \#11140050                                                                                                                                                                                                                                                        

  Other                          sheep serum                                            Thermo Fisher Scientific         535--81301                                                                                                                                                                                                                                                        

  Other                          skim milk                                              Wako                             \#190--12865                                                                                                                                                                                                                                                      

  Other                          tRNA                                                   Roche                            109--495                                                                                                                                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation of mutant mice {#s4-1}
-------------------------

All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the National Research Institute for Child Health and Development (permit numbers: 2004--003, 2014--001). To accomplish the *Lin28a* knockout, the targeting vector was constructed to replace the endogenous *Lin28a* locus with the Venus gene and PGK-neo cassette by homologous recombination in ES cells. The 5' and 3' sequences flanking the endogenous *Lin28a* locus were amplified by PCR from a C57BL/6N genomic *bacterial artificial chromosome* (BAC) clone (BACPAC Resource Center). The primer sequences used for homology arm cloning were as follows: 5' homology arm forward primer (Fp) NotI, 5′--TTGCGGCCGCGGCTCCCTTGCCTGGTCCTCCTGCCGATTC--3′; 5' homology arm reverse primer (Rp) SalI, 5′--GCGTCGACGGTCGTCTGCTGAGCCCGTGGCCCCGGG--3′; 3' homology arm Fp ClaI, 5′--GGATCGATTCGAGCTTGCGATTCAGCGGGCACACCTTAGG--3′; and 3' homology arm Rp AscI, 5′--AAGGCGCGCCAGGGTCTGGCAGCTGAGGAAGTTCCCCTAA--3′. These homology arms were cloned into a vector that incorporated both a neomycin-resistance cassette for positive selection and a diphtheria toxin A (*DT-A*) gene for negative selection. The targeting vector was linearized and electroporated into TT2F ES cells. Recombinant ES clones were isolated after culture in medium containing the G418 antibiotic and screened for proper integration by Southern blotting using the 5' probe, 3' probe, and neo cassette sequence. Two clones exhibited proper integration, as validated by genomic sequencing, and were chosen for microinjection into 8 cell stage embryos. The resulting chimeric offspring were crossed to C57BL/6N mice and germ-line transmission was confirmed by Southern blotting and PCR. The floxed PGK-neo cassette was removed by crossing with Meox2-Cre mice (The Jackson Laboratory). Genotyping of *Lin28a* mutant mice was performed by PCR analysis. Genomic DNA was isolated from mouse tail snips. Each tail snip was incubated at 50°C with DirectPCR Lysis reagent with Proteinase K for more than 6 hr, followed by heating at 80°C for 1 hr, to inactivate Proteinase K. The tail lysate (1 μL) was used as a PCR template. Genotyping PCR was carried out using GoTaq Flexi DNA Polymerase, according to the manufacturer's protocol. The primer sequences used for *Lin28a* genotyping PCR were as follows: *Lin28a* KO genotyping 1, 5′--TACAAGCCACTGGAACACCA--3′; *Lin28a* KO genotyping 2, 5′--GGGGGTTGGGTCATTGTCTTT--3′; and *Lin28a* KO genotyping 3, 5′--GTTCTGCTGGTAGTGGTCGG--3′.

For CRISPR/Cas9-mediated gene targeting via nonhomologous end joining ([@bib96]; [@bib38]), the guide RNA containing the target sequence of the *Cbx2* CDS (CTGAGCAGCGTGGGCGAGC) was synthesized in vitro using mMESSAGE mMACHINE T7 Kit and was purified using MegaClear Transcription Clean-Up kit, according to the manufacturer's instructions. A mixture containing 250 ng/μL of guide RNA and hCas9 mRNA was microinjected into the cytoplasm of a 1 cell stage embryo (C57BL/6N background). For genotyping, genomic DNA was isolated from mouse tail snips. Genotyping PCR was carried out using GoTaq Flexi DNA Polymerase, according to the manufacturer's protocol. The primer sequences used for *Cbx2* genotyping PCR were as follows: *Cbx2* CDS genotyping Fp, 5′--CCCTCTGGCCAAACAATAGCTTTCCGCAGGGACC--3′; and *Cbx2* CDS genotyping Rp, 5′--GCGCCACTTGACCAGGTACTCCAGCTTGCCCTGC--3′. The PCR products were treated with ExoSAP-IT and were then used as a template for direct sequencing. Sequence analysis of the *Cbx2* CDS locus was performed using F0 offspring, and mice that carried frameshift mutations were selected for further analysis.

HEK293T culture {#s4-2}
---------------

HEK293T cells were purchased from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% FBS and antibiotics. There is no mycoplasma contamination in this cell line.

Establishment of ES-Like cells {#s4-3}
------------------------------

*Lin28a*^--/--^ blastocysts were harvested and cultured on mouse embryonic fibroblasts (MEFs) in ES culture medium (15% FBS, 4.5 g/L of [d]{.smallcaps}-glucose, 1 × Glutamax, 1 mM sodium pyruvate, 1 × nonessential amino acids (NEAAs), 0.1 mM 2-mercaptoethanol, and 1 × 10^4^ units/mL of LIF in DMEM) with 3 μM of CHIR 99021 and 1 μM of PD0325901. Each colony was isolated and expanded, followed by genotyping PCR. Wt and *Lin28a*^--/--^ ES-like cells were stained with NBT/BCIP solution to test for alkaline phosphatase activity. There is no mycoplasma contamination in these cells. Western blotting and q-PCR analyses were performed for each genotype, as described below.

Western blotting {#s4-4}
----------------

Whole-protein extracts from the somites and neural tubes of E9.5 embryos were prepared for western blotting. Samples were separated using 10% SDS--PAGE and blotted onto PVDF membranes. The membranes were first incubated with blocking solution (5% skim milk in TBST) and then incubated with the primary antibody in blocking solution. Membranes were washed in TBST three times for 15 min and incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody in blocking solution. The blots were visualized using Chemi-Lumi One, Immobilon, SuperSignal West Femto Maximum Sensitivity Substrate, and LAS-3000 (Fujifilm), followed by analysis using the Multi Gauge Ver3.2 software. β-actin was measured as an internal control. The antibodies used and their dilutions were listed in Key Resources Table.

In situ hybridization {#s4-5}
---------------------

*Lin28a*^--/--^ embryos and Wt littermates were obtained by intercrossing *Lin28a*^+/--^ mice. Whole-mount in situ hybridization was performed as described previously ([@bib109]); the details of the probe sequence can be obtained from the 'EMBRYS' website (<http://embrys.jp/embrys/html/MainMenu.html>). Briefly, embryos were fixed in 4% PFA/PBT and dehydrated in a series of increasing MetOH concentrations. Rehydrated samples were bleached with 6% H~2~O~2~ in PBT and treated with 10 μg/mL of Protease K for 10 min at room temperature (RT), stopped with 0.2% glycine, and refixed with 4% PFA/0.2% glutaraldehyde in PBT for 20 min at RT. RNA hybridization was performed at 70°C for more than 14 hr, after prehybridization for 1 hr in hybridization buffer (50% formamide, 5 × SSC, 1% SDS, 50 μg/mL of tRNA, and 50 μg/mL of heparin in RNase-free H~2~O). Subsequently, embryos were washed three times in wash buffer 1 (50% formamide, 5 × SSC, and 1% SDS in RNase-free H~2~O) and twice in wash buffer 2 (50% formamide, 2 × SSC, and 5% Chaps in RNase-free H~2~O). After blocking with 10% sheep serum in TBST for 1 hr at RT, samples were incubated with an anti-DIG-AP Fab fragment antibody and 1% sheep serum in TBST overnight (O/N) at 4°C. After a series of washes with TBST, embryos were equilibrated in alkaline phosphatase buffer (NTMT) and developed with NBT/BCIP solution (Roche). After the color reaction, the embryos were rinsed in TBST several times and postfixed in 4% PFA/PBT at 4°C.

In situ hybridization of sections was performed on Wt and *Lin28a*^--/--^ embryos at E12.5, as described previously ([@bib90]). Embryos were fixed in 4% PFA/PBT, dehydrated in a series of increasing MetOH concentrations, and embedded in paraffin. Sagittal sections (10 μm) were stained with Alcian Blue and Fast Red to outline the pre-vertebrae. Deparaffinized and rehydrated sections were treated with 8 μg/mL of Proteinase K (Roche) in PBS for 10 min, and the reaction was stopped with 0.2% glycine in PBS. After postfixation with 4% PFA, samples were acetylated in acetylation buffer (100 mM triethanolamine, 2.5 mM acetic anhydride; pH was adjusted to 8.0 using HCl). Sections were incubated in prehybridization buffer (50% formamide, 5 × SSC) for 1 hr at 65°C. Subsequently, hybridization was performed O/N at 65°C using an RNA probe for *Hoxc13* in hybridization buffer (50% formamide, 5 × SSC, 10% dextran sulfate, 5 × Denhardt's solution, 0.1 mg/mL of salmon sperm DNA, and 0.25 mg/mL of tRNA). The sections were washed with 0.2 × SSC for 3 hr at 65°C and rinsed with neutralize tagment (NT) buffer (100 mM Tris-HCl, pH 7.5, 150 mM NaCl) for 5 min. After blocking with 10% sheep serum in NT buffer, samples were incubated with an anti-DIG-AP Fab fragment antibody and 1% sheep serum O/N at 4°C. After a series of washes with NT buffer, samples were equilibrated in NTM (100 mM NaCl, 100 mM Tris-HCl, pH 9.5, and 50 mM MgCl~2~) and developed using an NBT/BCIP solution. After the color reaction, the embryos were counterstained with Fast green.

Skeletal preparation {#s4-6}
--------------------

Whole-mount skeletal preparations of neonatal mice of each genotype were performed using Alcian Blue and Alizarin Red S staining. For RA treatment, 1 mg/kg of RA was injected intraperitoneally at 7.5 dpc, and the skeletal patterning of each genotype was analyzed at E15.5. The samples were fixed in 100% ethanol (EtOH) for 1--2 days after the majority of the skin and internal organs were removed. The 100% EtOH wash was changed several times. After fixation, the samples were incubated in Alcian Blue solution (0.03% Alcian Blue 8GX, 80% EtOH, and 20% acetic acid) for up to 2 days. The samples were rinsed in distilled water three times and incubated in Alizarin Red Solution (0.01% Alizarin Red S, 1% KOH in H~2~O) O/N. The samples were treated with discoloring solution (1% KOH, 20% glycerol in H~2~O) for 4--7 days. The samples were soaked in a series of glycerol/EtOH solutions (20% glycerol, 20% EtOH; 50% glycerol, 50% EtOH) and stored in 100% glycerol.

Quantitative PCR {#s4-7}
----------------

Total RNA was isolated from whole embryos ([Figure 3A and B](#fig3){ref-type="fig"}), or from dissected somites and neural tubes ([Figures 2A](#fig2){ref-type="fig"}, [3C and G](#fig3){ref-type="fig"}) at E9.5 using ISOGEN (Nippon Gene), according to the manufacturer's instructions. For SYBR green q-PCR, a complementary DNA (cDNA) was produced using Superscript II reverse transcriptase, 1 μg of total RNA, and an oligo(dT)18 primer. q-PCR analysis was performed using the SYBR Green PCR Master Mix and an ABI 7900HT instrument (Applied Biosystems). *Gapdh* was measured as an internal control to normalize sample differences. The primer sets used for all *Hox* genes were described by [@bib49]. The primer sequences used for other genes were as follows: *Lin28a* Fp1, 5′--CTCGGTGTCCAACCAGCAGT--3′; *Lin28a* Rp1, 5′--CACGTTGAACCACTTACAGATGC--3′; *Lin28a* Fp2, 5′--AGGCGGTGGAGTTCACCTTTAAGA--3′; *Lin28a* Rp2, 5′--AGCTTGCATTCCTTGGCATGATGG--3′; *Cbx2* Fp, 5′--AGGCCGAGGAAACACACAGT--3′; *Cbx2* Rp, 5′--GGAGGAAGAGGACGAACTGC--3′; *Oct3/4* Fp, 5′--GTTTCTGAAGTGCCCGAAGC--3′; *Oct3/4* Rp, 5′--GCGCCGGTTACAGAACCATA--3′; *Nanog* Fp, 5′--ACCTCAGCCTCCAGCAGATG--3′; *Nanog* Rp, 5′--ACCGCTTGCACTTCATCCTT--3′; *Sox2* Fp, 5′--GGCAGCTACAGCATGATGCAGGAGC--3′; *Sox2* Rp, 5′--CTGGTCATGGAGTTGTACTGCAGG--3′; *Gapdh* Fp, 5′--CCTGGTCACCAGGGCTGC--3′; and *Gapdh* Rp, 5′--CGCTCCTGGAAGATGGTGATG--3′.

For microRNAs, cDNAs were produced using the TaqMan MicroRNA Reverse Transcription kit according to the manufacturer's protocol. q-PCR was performed using TaqMan Rodent MicroRNA Array A and B and TaqMan MicroRNA Assays for *let-7a*, *let-7b*, *let-7c*, *let-7d*, *let-7e*, *let-7f*, *let-7g*, *let-7i*, *mir-98*, *mir-10a*, *mir-10b*, *mir-196a*, *mir-196b*, and *RNU6B. RNU6B* was measured as an internal control to normalize sample differences.

Luciferase assay {#s4-8}
----------------

The pLuc2 reporter vector was as described previously ([@bib64]). To create the *let-7* sensor vector, the chemically synthesized *let-7* complementary sequence was annealed and inserted between the EcoRI and XhoI sites. To create the pLuc2-candidate gene 3′UTR vector, the predicted *let-7* target sequence of each genes of 3′UTR was cloned into pLuc2. Fragment containing mutation in *let-7* target sequence were also cloned in pLux2. The miRNA precursor sequence (40 bp) was cloned into pcDNA3.1 and used as an miRNA-expressing vector. Transfection into HEK293T cells was performed using Lipofectamine 2000 or FugeneHD. The transfected cells were incubated for 48 hr, and luciferase activity was determined using the Dual-Glo Luciferase Assay System.

Chromatin immunoprecipitation {#s4-9}
-----------------------------

Harvested E9.5 embryos were dissected into somites and neural tubes. Genomic DNA was isolated from the yolk sac and genotyping PCR was performed. Samples were cryopreserved until use. For each assay, ChIP was performed on a pool of 10 embryos. Each antibody (5 μg) was used for immunoprecipitation. The antibodies used for ChIP were listed in Key Resources Table. The frozen samples were cross-linked with 1% formaldehyde in PBS for 10 min at RT. Cross-linking was stopped by adding 100 μL of 1.25 M glycine for 5 min at RT. Samples were washed with PBS and suspended in cell lysis buffer (10 mM Tris-HCl (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, and 1 mM PMSF). Nuclei were collected by centrifugation and resuspended in cell lysis buffer twice. Samples were suspended in 130 μL of nucleus lysis buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 1% SDS, and 1 mM PMSF) and transferred into Covaris microTUBEs. The chromatin was sheared by sonication (peak power, 105; duty factor, 5.0; cycles/burst, 200; duration, 10 min). The sheared DNA was diluted in IP dilution buffer (20 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM PMSF), added to antibody beads, and rotated O/N at 4°C. Precipitated beads with chromatin were washed four times with ChIP wash buffer 1 (20 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM PMSF) and twice with ChIP wash buffer 2 (20 mM Tris-HCl (pH 8.0), 2 mM EDTA (pH 8.0), 500 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM PMSF). After washing with TE, chromatin was isolated using nucleus lysis buffer at 65°C. The isolated chromatin was de-cross-linked for 6 hr at 65°C. After Proteinase K treatment, DNA was purified using a PCR purification kit (elute in 50 μL of H~2~O). q-PCR was performed on immunoprecipitated DNA and input DNA and analyzed for the efficiency of immunoprecipitation by each antibody. The primer sequences used for ChIP q-PCR were as follows: ChIP *Hoxa1* Fp, 5′--TGAGAAAGTTGGCACGGTCA--3′; ChIP *Hoxa1* Rp, 5′--CACTGCCAAGGATGGGGTAT--3′; ChIP *Hoxa2* Fp, 5′--CTCCAAGGAGAAGGCCATGA--3′; ChIP *Hoxa2* Rp, 5′--CGACAGGGGGAAAAGATGTC--3′; ChIP *Hoxa3* Fp, 5′--GTTGTCGCTGGAGGTGGAG--3′; ChIP *Hoxa3* Rp, 5′--GCCAGAGGACGCAGGAAAT--3′; ChIP *Hoxa4* Fp, 5′--AACGACACCGCGAGAAAAAT--3′; ChIP *Hoxa4* Rp, 5′--GGGAACTTGGGCTCGATGTA--3′; ChIP *Hoxa5* Fp, 5′--TCCCCCGAATCCTCTGTATC--3′; ChIP *Hoxa5* Rp, 5′--ATTGCATTTCCCTCGCAGTT--3′; ChIP *Hoxa6* Fp, 5′--GTTCGGCCATCCAGAAACA--3′; ChIP *Hoxa6* Rp, 5′--CCCCTCTGCAGGACTGTGAT--3′; ChIP *Hoxa7* Fp, 5′--AGCCTTCACCCGACCTATCA--3′; ChIP *Hoxa7* Rp, 5′--AGCACAGCCTCGTTCTCTCC--3′; ChIP *Hoxa9* Fp, 5′--CCTCCCGGGTTAATTTGTAGC--3′; ChIP *Hoxa9* Rp, 5′--CCCCTGCCTTGGTTATCCTT--3′; ChIP *Hoxa10* Fp, 5′--CCTAGACTCCACGCCACCAC--3′; ChIP *Hoxa10* Rp, 5′--GGCTGGAGACAGCTCCTCA--3′; ChIP *Hoxa11* Fp, 5′--AGAGCTCGGCCAACGTCTAC--3′; ChIP *Hoxa11* Rp, 5′--AACTGGTCGAAAGCCTGTGG--3′; ChIP *Hoxa13* Fp, 5′--ACTTCGGCAGCGGCTACTAC--3′; ChIP *Hoxa13* Rp, 5′--CATGTACTTGTCGGCGAAGG--3′; ChIP *Hoxc13* Fp, 5′--CAGGAGACCCAGGCTTAGCA--3′; ChIP *Hoxc13* Rp, 5′--GCATGCGGACACACTTCATT--3′; ChIP *Hoxd12* Fp, 5′--GGAGATGTGTGAGCGCAGTC--3′; ChIP *Hoxd12* Rp, 5′--CTGCCATTGGCTCTCAGGTT--3′.

Knockdown of *let-7* in ES-like cells {#s4-10}
-------------------------------------

To knockdown *let-7* expression, guide-RNAs targeting the *let-7* family members were constructed. The target sequences of *let-7* family members were as follows: *let-7a-1*, TAGTAGGTTGTATAGTTTT; *let-7a-2* and *let-7c-1*, GGTTGAGGTAGTAGGTTGT; *let-7b*, TAGTAGGTTGTGTGGTTTC; *let-7c-2*, TAGTAGGTTGTATGGTTTT; *let-7d*, TAGTAGGTTGCATAGTTTT; *let-7e*, GTAGGAGGTTGTATAGTTG; *let-7f-1*, TAGTAGATTGTATAGTTGT; *let-7f-2*, TAGTAGATTGTATAGTTTT; *let-7g*, TAGTAGTTTGTACAGTTTG; and *let-7i*, AGGTAGTAGTTTGTGCTGT (see also [Figure 5H](#fig5){ref-type="fig"}). Four guide-RNA-expressing plasmid vectors and an hCas9 vector (500 ng each) were transfected into 1 × 10^6^ cells using the Neon transfection system, according to the manufacturer's instructions. Transfected cells were cultured in ES medium containing 0.5 μg/mL of puromycin for 2 days. Each colony was isolated and expanded, followed by PCR and sequence analysis. The primer sequences used for *let-7* genotyping PCR were as follows: *let-7a-1* Fp, 5′--GGCTTATAGCCCAGGTGTATCAT--3′; *let-7a-1* Rp, 5′--ACTTGCCCATTCCCATCATC--3′; *let-7a-2* Fp, 5′--TTCTTATGAACGGCCCGAGT--3′; *let-7a-2* Rp, 5′--CCGTTGATCACCTGTGTTGC--3′; *let-7c-1* Fp, 5′--TGGTAGGCACAGGCCTTTCT--3′; *let-7c-1* Rp, 5′--CAATGTGTGGTTGGCGATCT--3′; *let-7b* Fp, 5′--TTTGCTCGCTGCTAATGGAA--3′; *let-7b* Rp, 5′--GGCCTCATGGACTCATGACA--3′; *let-7c-2* Fp, 5′--GTCTCCCCGTCTCCCCTTAC--3′; *let-7c-2* Rp, 5′--AGGTGCCCTGAAAATGCTGT--3′; *let-7d* Fp, 5′--TTTGGCTTTTGCCAAGATCA--3′; *let-7d* Rp, 5′--TGCTTTCCAAAACTTCCCAGT--3′; *let-7e* Fp, 5′--TGAATTCCTGGGTTCCTTGG--3′; *let-7e* Rp, 5′--TCAAGATGGCATAGAGACTGCAA--3′; *let-7f-1* Fp, 5′--GATGATGGGAATGGGCAAGT--3′; *let-7f-1* Rp, 5′--CCAAAAGGCCTGGTCCTAGA--3′; *let-7f-2* Fp, 5′--TCTTGTGTGCTTGTCTCCCATT--3′; *let-7f-2* Rp, 5′--CTGAGAACCACTGCCACCAG--3′; *let-7g* Fp, 5′--TGGTGTATTTCTTTTGTTGGGTTG--3′; *let-7g* Rp, 5′--TGAACAACTCCAAGCCTCTCA--3′; *let-7i Fp*, 5′--GGGCCCCGGATGTAAGATGG--3′; and *let-7i* Rp, 5′--CCTCGAGAACGAAACCCAAC--3′. The PCR products were treated with ExoSAP-IT (Affimetrix) and used as templates for direct sequencing. Clones of *let-7* family members with deletions of several nucleotides were selected for further analysis.

Embryoid bodies were produced from each clone, and expression changes of *Hox* genes were analyzed over 3 days. Cells (1 × 10^6^) were suspended in 1 mL of DMEM with 10% FBS and plated in low-adhesion culture dishes. After several hours, self-aggregated ES-like cells were resuspended in 10 mL of medium. The medium was changed every other day. RNA isolation and q-PCR analysis are described above.

Statistical analyses {#s4-11}
--------------------

Two-tailed independent Student's *t*-tests were used to determine all *P* values. Asterisks indicate statistically significant differences (at p\<0.05), whereas n.s. indicates an absence of significance.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100009619Japan Agency for Medical Research and Development JP17gm0810008 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/100000069National Institute of Arthritis and Musculoskeletal and Skin Diseases AR050631 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/501100001691Japan Society for the Promotion of Science 15H02560 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/501100003382Core Research for Evolutional Science and Technology JP15gm0410001 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/501100001691Japan Society for the Promotion of Science 13J00119 to Tempei Sato.

-   http://dx.doi.org/10.13039/501100001691Japan Society for the Promotion of Science 26113008 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/100000069National Institute of Arthritis and Musculoskeletal and Skin Diseases AR065379 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/501100001691Japan Society for the Promotion of Science 26113008 to Hiroshi Asahara.

-   http://dx.doi.org/10.13039/501100001691Japan Society for the Promotion of Science 15K15544 to Hiroshi Asahara.

We thank Dr. Hirohito Shimizu for the technical advice on RA treatment assay, Ms. Moe Tamano for the embryo manipulation, Drs. Satohsi Yamashita and Kazuhiko Nakabayashi for technical advice on ChIP assay, Prof. Mikiko C Siomi for critical and helpful discussion, and Ms. Izumi A Tsune and Dr. Spencer J Spratt for their support in manuscript preparation. We also thank all other Asahara lab members for their support.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration.

Conceptualization, Data curation, Funding acquisition, Validation, Investigation, Methodology.

Investigation.

Investigation.

Conceptualization, Investigation.

Conceptualization, Supervision, Investigation.

Conceptualization, Supervision, Investigation.

Supervision, Investigation.

Supervision, Investigation.

Investigation.

Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Validation, Investigation, Methodology, Project administration.

Animal experimentation: All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the National Research Institute for Child Health and Development (permit numbers: 2004-003, 2014-001).

Additional files {#s6}
================

###### Survival rate of *Lin28a* mutant mice at various stages.

Data availability {#s7}
=================

All data generated or analysed during this study are included in the manuscript and supporting files.

10.7554/eLife.53608.sa1

Decision letter

Robertson

Elizabeth

Reviewing Editor

University of Oxford

United Kingdom

Ambros

Victor

Reviewer

University of Massachusetts Medical School

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The paper demonstrates a role for the temporal regulatory microRNA let-7, and its mutual target, Lin-28, in skeletal anterior-posterior patterning. These findings reinforce the importance of precise timing and dosage of gene activity in achieving the proper spatial patterning of Hox gene activity.

**Decision letter after peer review:**

Thank you for submitting your article \"Lin28a/let-7 Pathway Modulates the Hox Code via Polycomb Regulation during Axial Patterning in Vertebrates\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Clifford Rosen as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Sato et al. demonstrate a role in skeletal anterior-posterior patterning for the temporal regulatory microRNA let-7, and its mutual target, Lin-28. This is an important advance, because it reinforces the importance of precise timing and dosage of gene activity in achieving the proper spatial patterning of Hox gene activity. In addition the authors show that the action of Lin-28a/let-7 in axial patterning very likely reflects the regulation of the PcG gene Cbx2, thus linking these temporal regulators to the process of setting up the chromatin state of Hox genes. They exploited an ES cell differentiation model to critically test for whether let-7 family microRNAs mediate the effects on Hox gene expression of Lin-28a loss-of-function, and also to test for whether the let-7 complementary sites in the Cbx2 3\' UTR are required to mediate the action of let-7 in this context.

Essential revisions:

This work is a technically thorough investigation of the phenotype of Lin28 mutant mice. However, the reviewers point out that the relatively single-sighted focus on Hox genes likely represents a \'miss\' in interpreting the phenotype. There are many inconsistencies in this focus. Among them is using the term \'homeotic transformations\' is technically acceptable perhaps, but the authors are really reporting a shortening of the axis with perhaps a \'perturbation\' of C1/C2. These are mild \'transformations\' to begin with and not really homeotic. The more substantial issue with this version of the manuscript is that it does not take into account a publication from February from Moises Mallo\'s laboratory (Aires, et al., Dev Cell), which closely examined a network of factors, including Lin28 in during tailbud transition. It seems the authors are not aware of this work that profoundly impacts the interpretation of this phenotype. It is critical that these authors carefully read this paper and rewrite theirs and resubmit with what seems likely to be a re-interpretation of their interesting phenotype -- or, if not that, their interpretation in light of this work.

Reviewer \#1:

1\) It is not clear what the RA experiment adds to the story. As it stands, the argument is based on saying, \"It is known that Hox genes are modulated by retinoic acid...\" and then, \"Therefore we administered...\". The logic of the experiment needs to be more explicitly laid out. Also, the conclusions are not clearly linked to the result. At the end of the paragraph, the conclusion is drawn that the sensitivity of Lin-28a+/- to RA indicates that, "Lin-28a acts upstream of the Hox genes.\" But it is not immediately apparent that the observed synergy between Lin-28a+/- and RA might not be consistent with alternative interpretations, such as parallel pathways.

2\) \"To support this concept further....\" is not really a satisfactory rationale for this genetic interaction experiment. The logic should be spelled out more explicitly. There is a related problem with the statement of the conclusions of the experiment, in the final sentence of the paragraph. \"...these results suggest that the Lin-28a/let-7 reciprocal feedback regulates Cbx2 expression....\" The authors need to tell us exactly why the synergy between Lin-28+/- and Cbx2+/- means that Lin-28a regulates Cbx2. In particular, does this result necessarily rule out the possibility that Cbx2 and Lin-28a could regulated skeletal patterning by parallel pathways? Also, the statement that \"...this pathway is required for skeletal patterning...\" is a bit too strong, as \"required for\" would imply strong loss-of-function phenotypes. More appropriate would be something like, \"...this pathway contributes to the regulation of proper skeletal patterning...\"

3\) Subsection "Let-7 knockdown rescues Hox gene dysregulation in Lin28a^--/--^ cells", third paragraph: The data in Figure 5I needs to be quantitated; i.e., band intensities scanned. This is also the case for Figure 3---figure supplement 2. In order to argue that there was indeed a change in protein level, replicate samples need to be measured quantitatively, and statistical tests should be applied.

4\) Subsection "Let-7 knockdown rescues Hox gene dysregulation in Lin28a^--/--^ cells", last paragraph: Referring to Figure 5L this point is confusing, because the depiction of the model in Figure 5L does not really account for how reduced Lin-28a would result in posterior transformations in cell fate, which is what the results indicate. Now, in the Discussion section (see below), the model is much better justified by taking into account what is known about the importance of timing in the establishment of proper Hox gene expression patterns. By the way, one source of confusion (at least for this reader) is the fact that the down regulation of Lin-28a during development occurs in a posterior-to-anterior direction; this led me to think in terms of the differential temporal regulation of posterior vs. anterior Hox genes by Lin-28a during e9.5-e10-5. But, unless I am still confused, it seems that the axial sweep of Lin-28a down regulation is not in itself terribly germane to the model.

5\) Discussion, first paragraph: Here the model is made much more understandable by linking hox gene expression patterns to the timing of their repression or activation. Another key point is made where it is stated that \"PcG genes should be repressed prior to the initiation of Hox gene expression to open the chromatin....\". The diagrams shown in Figure 5L does not effectively convey these important temporal elements of the authors\' model.

6\) Discussion, second paragraph: See comments above about the need to explicate the logic for how the genetic interaction results support the conclusions. Don\'t get me wrong; I agree that these results support the model, but the logic is just not expressed in the narrative. Note, however that there are always caveats about interpreting genetic interactions too definitively. For example, the authors\' results are also consistent with Lin-28a and Cbx2 acting in the same linear pathway, or in parallel pathways.

7\) Figure 5 legend: As discussed above, I do not find the diagram in Panel L terribly helpful in understanding precisely what is the authors\' model for how the developmental dynamics of Lin-28a/let-7 activity impacts hox gene spatial expression patterns. It is clear from the diagram that the \"Time dependent down-regulation of Lin-28a\" is important, and emphasis is placed on the fact that this down-regulation occurs progressively from the anterior towards the posterior of the embryo. However, there is no depiction of how those dynamics are connected to Hox patterning. In particular, the model depicts a transition from broad PcG expression at 9.5 to a posterior-enriched PcG expression pattern at 10.5, which seems to imply that the repression of Lin-28a by let-7 is similarly from anterior to posterior; but I\'m not certain if that is the authors\' intent. Also, the model also seems to suggest that the Lin-28a/let-7 circuit could be entirely responsible for the posterior-anterior down-regulation of PcG gene expression, but of course that is not the case.

Reviewer \#2:

Introduction, last paragraph -- as stated above, the phenotype is somewhat mild (except for the tail, i.e. Aires, et al) and is more accurately a shortening of the axis, not a homeotic transformation. Likewise, one would have to hypothesize a \'dysregulation of Hox genes, but the authors see an increase later. As shown by clear genetic work (Wellik and Capecchi, 2003, McIntyre, et al., 2007), Hox genes are not very sensitive to dosage! There is no reason to hypothesize that increasing expression -- except for Hox13 (Mallo work) -- would lead to changes observed here. The interpretation is highly consistent with Aires, et al., in axis elongation and conversion to tail bud!

Subsection "Hox genes are dysregulated in Lin28a^--/--^ mice": \'global transformation\' is a very liberal interpretation of phenotype. It is mainly tail!

The RA experiments add little in this reviewer\'s view.

The let7 activity becomes more interesting in light of Aires, et al. and its effects on lin28 are highly interesting (if also supporting the strong conservation one might expect from previous work). The ES cell work is not highly compelling in light of Aires, et al., but could perhaps be used in light of this context...

The data supporting Cbx2 mutants as having \'homeotic transformations\' is less supported than for Lin28. This statement should be highly modified or removed. It is very unclear why authors did not look at double mutants. One suspects this may not support \'Hox\' part of story, but in light of Aires, et al., this phenotype may be highly interesting and allow support of an alternative interpretation. This reviewer is certainly curious about what happens! And a reinterpretation in general may be warranted here especially.

Subsection "Lin28a/let-7 pathway modulates PRC1 occupancy at posterior Hox loci" -- very odd references to Hox mutants -- the paralog mutants that establish clear homeosis as predicted from *Drosophila* work should be discussed here (Horan, van den Akker, Wellik, McIntyre).

Discussion and Reinterpretation of let7 experiments should be re-worked in light of Aires.

Reviewer \#3:

1\) Lin28a is ubiquitously expressed in embryonic development. Hox genes as well as Cbx2 have been shown to regulate AP patterning and other developmental processes such as limb patterning. Are there any other developmental defects observed in the Lin28a-/- mice that also support the role of Lin28a in regulating Cbx2 and Hox codes?

2\) Most importantly, Figure 4H indicates that only 5\' Hox genes and posterior regions should be affected in the Lin28a-/- mice, but homeotic transformations were seen in the cervical, thoracic and lumbosacral regions where Hoxc13 and Hoxd12 were not expressed.

3\) The expression of Hox genes should be examined in more detail in both WT and mutant embryos at the same stages. In Figure 2B, how were the expression domains of Hoxc13 and Hoxd12 demarcated?

4\) In Figure 2---figure supplement 1, comparison of Hox gene expression patterns should be done at the same stages with similar somite numbers and the expression domain should be properly demarcated with somite \"landmarks\".

5\) The readouts of genetic interaction experiments by crossing to Cbx2 mutants and RA treatment were not robust. If posterior regions were more affected, homeotic transformation in the lumbosacral regions should be shown.

6\) There seems to be some discrepancy in the regulation of Hox genes by Lin28a in vitro and in vivo. For instance, Hoxa11 expression was altered in vitro, but not in the somites in development by WISH (Figure 4E).

10.7554/eLife.53608.sa2

Author response

> Essential revisions:
>
> This work is a technically thorough investigation of the phenotype of Lin28 mutant mice. However, the reviewers point out that the relatively single-sighted focus on Hox genes likely represents a \'miss\' in interpreting the phenotype. There are many inconsistencies in this focus. Among them is using the term \'homeotic transformations\' is technically acceptable perhaps, but the authors are really reporting a shortening of the axis with perhaps a \'perturbation\' of C1/C2. These are mild \'transformations\' to begin with and not really homeotic.

We agree with the reviewer's comment that our observations of Lin28a-/- mice are rather mild \'transformations\' not apparent \'homeotic transformations\'. To avoid being potentially misleading in the interpretation of the phenotype, we have carefully revised the specific terms for each observed phenotype. As for skeletal patterning defects of C1/C2, we rephrase \'homeotic transformations\' using other words such as \'skeletal transformation\'; Abstract, Introduction, Results, Discussion and Figure 1 legend.

> The more substantial issue with this version of the manuscript is that it does not take into account a publication from February from Moises Mallo\'s laboratory (Aires, et al., Dev Cell), which closely examined a network of factors, including Lin28 in during tailbud transition. It seems the authors are not aware of this work that profoundly impacts the interpretation of this phenotype. It is critical that these authors carefully read this paper and rewrite theirs and resubmit with what seems likely to be a re-interpretation of their interesting phenotype -- or, if not that, their interpretation in light of this work.

We appreciate the reviewer's advice. Although we had noted, and cited,Dr. Mallo\'s report (Aires, et al., Dev Cell) in the Discussion of the original manuscript, we should have discussed the comparison between their finding and our observation in more depth. This has now been included in the revised manuscript, in the Abstract, the Introduction, the Results and extensively in the Discussion.

> Reviewer \#1:
>
> 1\) It is not clear what the RA experiment adds to the story. As it stands, the argument is based on saying, \"It is known that Hox genes are modulated by retinoic acid...\" and then, \"Therefore we administered...\". The logic of the experiment needs to be more explicitly laid out. Also, the conclusions are not clearly linked to the result. At the end of the paragraph, the conclusion is drawn that the sensitivity of Lin-28a+/- to RA indicates that, "Lin-28a acts upstream of the Hox genes.\" But it is not immediately apparent that the observed synergy between Lin-28a+/- and RA might not be consistent with alternative interpretations, such as parallel pathways.

We thank the reviewer for this comment and have better explained the logic of the experiment in the revised manuscript (subsection "Hox genes are dysregulated in Lin28a--/-- mice). Specifically, we hypothesized that the patterning defects of vertebrae observed in *Lin28a*^--/--^ mice were caused by the perturbation of *Hox* gene expression. To test that, we investigated the effects of perturbation of Hox gene expression by RA on skeletal pattern formation in Lin28a mutants. We conclude more cautiously by now saying that the results show that Hox gene perturbation by RA administration enhanced the Lin28a+/- and -/- phenotypes. In particular, since RA treated Lin28a+/- shows the same phenotype as untreated Lin28a-/-, we consider that there is a possibility that dysregulation of *Hox* genes might be responsible for the skeletal patterning defects in *Lin28a*^--/--^mice (Figure 2E).

> 2\) \"To support this concept further....\" is not really a satisfactory rationale for this genetic interaction experiment. The logic should be spelled out more explicitly. There is a related problem with the statement of the conclusions of the experiment, in the final sentence of the paragraph. \"...these results suggest that the Lin-28a/let-7 reciprocal feedback regulates Cbx2 expression....\" The authors need to tell us exactly why the synergy between Lin-28+/- and Cbx2+/- means that Lin-28a regulates Cbx2. In particular, does this result necessarily rule out the possibility that Cbx2 and Lin-28a could regulated skeletal patterning by parallel pathways? Also, the statement that \"...this pathway is required for skeletal patterning...\" is a bit too strong, as \"required for\" would imply strong loss-of-function phenotypes. More appropriate would be something like, \"...this pathway contributes to the regulation of proper skeletal patterning...\"

We thank the reviewer for this helpful comment and apologise for the lack of clarity in the original version, and appearing to overinterpret the data. We now better explain the rationale, specifically that Cbx2 is a polycomb protein that epigenetically regulates Hox genes, and cite a new reference showing that ablation of Cbx2 shows skeletal patterning defects (Core et al., 1997), leading us to speculate that decreased expression of Cbx2 might cause the abnormal skeletal formation in *Lin28a*^-/-^mice. We also more carefully describe the *Cbx2* homozygous mutant phenotype, and describe our reasoning why dysregulation of *Cbx2* might be responsible for the phenotype of *Lin28a*^--/--^mice, as well as being more cautious in our interpretations, for example by concluding that this pathway contributes to the regulation of proper skeletal patterning, as suggested. See subsection "Lin28a regulates Cbx2 expression via let-7 repression".

> 3\) Subsection "Let-7 knockdown rescues Hox gene dysregulation in Lin28a^--/--^ cells", third paragraph: The data in Figure 5I needs to be quantitated; i.e., band intensities scanned. This is also the case for Figure 3---figure supplement 2. In order to argue that there was indeed a change in protein level, replicate samples need to be measured quantitatively, and statistical tests should be applied.

We have now quantified these data using imageJ, and added them to the revised Figure 5I and Figure 3---figure supplement 2.

> 4\) Subsection "Let-7 knockdown rescues Hox gene dysregulation in Lin28a^--/--^ cells", last paragraph: Referring to Figure 5L this point is confusing, because the depiction of the model in Figure 5L does not really account for how reduced Lin-28a would result in posterior transformations in cell fate, which is what the results indicate. Now, in the Discussion section (see below), the model is much better justified by taking into account what is known about the importance of timing in the establishment of proper Hox gene expression patterns. By the way, one source of confusion (at least for this reader) is the fact that the down regulation of Lin-28a during development occurs in a posterior-to-anterior direction; this led me to think in terms of the differential temporal regulation of posterior vs. anterior Hox genes by Lin-28a during e9.5-e10-5. But, unless I am still confused, it seems that the axial sweep of Lin-28a down regulation is not in itself terribly germane to the model.

We apologize for the difficulty of understanding the contents of the figure. We revised the model with your helpful suggestions (Figure 5L).

> 5\) Discussion, first paragraph: Here the model is made much more understandable by linking hox gene expression patterns to the timing of their repression or activation. Another key point is made where it is stated that \"PcG genes should be repressed prior to the initiation of Hox gene expression to open the chromatin....\". The diagrams shown in Figure 5L does not effectively convey these important temporal elements of the authors\' model.

We thank the reviewer for this helpful comment. We have revised the diagram with the temporal regulation of gene expression as described above.

> 6\) Discussion, second paragraph: See comments above about the need to explicate the logic for how the genetic interaction results support the conclusions. Don\'t get me wrong; I agree that these results support the model, but the logic is just not expressed in the narrative. Note, however that there are always caveats about interpreting genetic interactions too definitively. For example, the authors\' results are also consistent with Lin-28a and Cbx2 acting in the same linear pathway, or in parallel pathways.

We thank the reviewer for this helpful comment and have revised the manuscript to address this concern, Discussion, third paragraph.

> 7\) Figure 5 legend: As discussed above, I do not find the diagram in Panel L terribly helpful in understanding precisely what is the authors\' model for how the developmental dynamics of Lin-28a/let-7 activity impacts hox gene spatial expression patterns. It is clear from the diagram that the \"Time dependent down-regulation of Lin-28a\" is important, and emphasis is placed on the fact that this down-regulation occurs progressively from the anterior towards the posterior of the embryo. However, there is no depiction of how those dynamics are connected to Hox patterning. In particular, the model depicts a transition from broad PcG expression at 9.5 to a posterior-enriched PcG expression pattern at 10.5, which seems to imply that the repression of Lin-28a by let-7 is similarly from anterior to posterior; but I\'m not certain if that is the authors\' intent. Also, the model also seems to suggest that the Lin-28a/let-7 circuit could be entirely responsible for the posterior-anterior down-regulation of PcG gene expression, but of course that is not the case.

We thank the reviewer for helpful comments and suggestions. We have revised the diagram to accommodate the temporal regulation of gene expression as described above (response for reviewer's comment \#4), and to explain our hypothesis that upregulation of let-7 in Lin28a-/- mice leads to decreased Cbx2 expression and subsequent PRC1 occupancy at Hox loci, which causes the disruption of the "Hox code." *Lin28a* expression gradually diminishes from anterior to posterior during embryogenesis, however, it is not implies that Cbx2 expression is also downregulated from anterior to posterior.

> Reviewer \#2:
>
> Introduction, last paragraph -- as stated above, the phenotype is somewhat mild (except for the tail, i.e. Aires, et al) and is more accurately a shortening of the axis, not a homeotic transformation. Likewise, one would have to hypothesize a \'dysregulation of Hox genes, but the authors see an increase later. As shown by clear genetic work (Wellik and Capecchi, 2003, McIntyre, et al., 2007), Hox genes are not very sensitive to dosage! There is no reason to hypothesize that increasing expression -- except for Hox13 (Mallo work) -- would lead to changes observed here. The interpretation is highly consistent with Aires, et al., in axis elongation and conversion to tail bud!

We appreciate the comment. To avoid a potentially misleading description of the phenotype, we have now carefully replaced every instance of 'homeotic transformation', and used other wording, including \'skeletal transformation\' and 'skeletal patterning': Abstract, Introduction, Results, Discussion and Figure 1 legend.

Although we indeed noted and citedDr. Mallo\'s report (Aires, et al., Dev Cell) in the Discussion of our original manuscript, we appreciate now that we should have discussed the comparison between their findings and our observations in more depth. This has now been included in the revised manuscript, in the Abstract, the Introduction, the Results and extensively in the Discussion.

> Subsection "Hox genes are dysregulated in Lin28a^--/--^ mice": \'global transformation\' is a very liberal interpretation of phenotype. It is mainly tail!
>
> The RA experiments add little in this reviewer\'s view.

We have revised the manuscript to describe that *Lin28a*^--/--^mice exhibited multiple transformations, and have tried to better rationalize and explain the RA experiment. Briefly, we used the RA experiment to support the model that *Lin28a* acts upstream of the *Hox* genes, and that dysregulation of *Hox* genes might be responsible for the phenotype of *Lin28a*^--/--^mice (Figure 2E). We therefore think including it in the manuscript is justified and does add value.

> The let7 activity becomes more interesting in light of Aires, et al. and its effects on lin28 are highly interesting (if also supporting the strong conservation one might expect from previous work). The ES cell work is not highly compelling in light of Aires, et al., but could perhaps be used in light of this context...

As mentioned above, we have revised the Discussion to include more in-depth discussion of the previous findings by Aires et al. Briefly, they showed that Lin28 and Hox13 had opposite functions in tail bud proliferation, suggesting that the balance of the expression of those two genes, which might be regulated by GDF signaling, is one of the determinants of tail length. Our results revealed the epigenetic inhibition of HoxPG13 by the Lin28a/let-7/Cbx2 pathway, which might be one of the mechanisms that explains the antagonistic function of Lin28a and HoxPG13 in axial elongation as well as in skeletal patterning. In Figure 5, we used embryoid bodies as a model and tested whether that Hox gene dysregulation could be rescued by knockdown of let-7 or Cbx2 3'UTR mutation. Unfortunately, we tried to test Hox13 expression as well, however, unfortunately, Hox13 was below the detection limit and could not be verified in this differentiation assay. However, we could rescue the gene expression Hox11 and Hox12 in Lin28a-/- cells, and these results suggest a new role of the Lin28a/let-7 pathway in the modulation of the "Hox code."

> The data supporting Cbx2 mutants as having \'homeotic transformations\' is less supported than for Lin28. This statement should be highly modified or removed. It is very unclear why authors did not look at double mutants. One suspects this may not support \'Hox\' part of story, but in light of Aires, et al., this phenotype may be highly interesting and allow support of an alternative interpretation. This reviewer is certainly curious about what happens! And a reinterpretation in general may be warranted here especially.

Both Lin28a-/- mice (in this study) and Cbx2-/- mice (Coré et al., 1997; Katoh-Fukui et al., 1998, in this study) exhibited skeletal transformations in the C1/C2 region, T13/L1 region, and L6/S1 region. In the case of Lin28a;Cbx2 double mutant mice, ablation or truncation of the 13^th^ pair of ribs were observed (Figures 3I and 3J), although the *Lin28*+/-- and *Cbx2*+/-- single mutants did not show any obvious phenotypic irregularities. In the lumbosacral region, no additional phenotypes were observed in the double mutants, since almost all of the Lin28a+/- mice showed the same phenotype as the Lin28a-/- mice, which had only five lumbar vertebrae (Table 1). In caudal vertebrae, there were also no additional phenotypes in Lin28a;Cbx2 double mutant mice. Unfortunately, we could not obtain and analyze *Lin28a*/*Cbx2* double KO mice. This is probably because most *Lin28a*^-/-^ exhibited embryonic lethality, and *Cbx2*^-/-^also showed perinatal or postnatal lethality.

Recently, the mechanism of tail bud elongation regulation by Lin28a and Hox13 has been reported (Aires et al., 2019). According to Aires et al., Lin28a/b genes promote and Hox13 genes restrict tail bud progenitor expansion downstream of Gdf11. Elevated Hox13 expression also directly or indirectly suppresses Lin28, leading to shortening of the tail. Since the expression of Hox13 is increased in Lin28a-/-, shortening of the tail is considered to be due to abnormal expression of Hox13. Cbx2 epigenetically suppresses Hox13, and in fact, histone modification of the Hox13 loci was altered in Lin28a-/- mice.　Thus, Lin28a/let-7-mediated Hox13 regulation by Cbx2 might be required for tail bud elongation and vertebrae formation. However, Cbx2-deficient mice did not show caudal vertebral defects and there was no effect on the tail of the Lin28a/Cbx2 double mutant. These results indicate that Hox13 regulation by Lin28a, via both Cbx2-dependent and -independent pathways, might be involved in tail bud progenitor expansion.

> Subsection "Lin28a/let-7 pathway modulates PRC1 occupancy at posterior Hox loci" -- very odd references to Hox mutants -- the paralog mutants that establish clear homeosis as predicted from *Drosophila* work should be discussed here (Horan, van den Akker, Wellik, McIntyre).

We apologize for the omission. We now cite these papers in the Introduction.

> Discussion and Reinterpretation of let7 experiments should be re-worked in light of Aires.

We have reworked the manuscript as described above.

> Reviewer \#3:
>
> 1\) Lin28a is ubiquitously expressed in embryonic development. Hox genes as well as Cbx2 have been shown to regulate AP patterning and other developmental processes such as limb patterning. Are there any other developmental defects observed in the Lin28a-/- mice that also support the role of Lin28a in regulating Cbx2 and Hox codes?

As the reviewer points out, Hox mutant mice show multiple phenotypes, including skeletal patterning defects in both vertebrae and appendages. We found abnormal expression of posterior Hox genes such as Hox12 and Hox13, which are critical for limb patterning, however, there were no abnormalities on limb development. These results indicate the existence of different mechanisms for the regulation of posterior Hox genes by Lin28a in the vertebrae and limb bud.

Previously two independent Cbx2 mutants were generated by different groups (Coré et al., 1997; Katoh-Fukui et al., 1998). Both groups reported that Cbx2 KO mice exhibited skeletal patterning defects, neonatal and postnatal lethality with abnormal body weight. Moreover, Cbx2 KO mice showed male to female sex reversal (Katoh-Fukui et al., 1998), abnormal lymphocyte differentiation, and decreased proliferation of splenocytes and fibroblasts (Coré et al., 1997). Lin28a-/- mice showed skeletal defects similar to that observed in Cbx2 KO mice, however, the other phenotypes, such as sex determination defects, were not found in Lin28a-/- mice. We have not examined lymphocytes and fibroblasts, but in Lin28a-/- ES-like cells that we established in this report, there were no abnormalities in cell proliferation.

> 2\) Most importantly, Figure 4H indicates that only 5\' Hox genes and posterior regions should be affected in the Lin28a-/- mice, but homeotic transformations were seen in the cervical, thoracic and lumbosacral regions where Hoxc13 and Hoxd12 were not expressed.

We thank the reviewer for this important comment. Although we do not have a clear answer yet, we considered some possible explanations for the cause of the phenotype in the cervical, thoracic and lumbosacral regions: it is possible that the skeletal pattern was perturbed due to an abnormality in the cell fate determination of the mesenchymal system and the nervous system.　We have revised the manuscript to include a discussion of this issue in the Discussion (second paragraph).

In addition, we have revised and simplified Figure 4H to enhance the reader's understanding.

> 3\) The expression of Hox genes should be examined in more detail in both WT and mutant embryos at the same stages. In Figure 2B, how were the expression domains of Hoxc13 and Hoxd12 demarcated?

WISH was performed using wild-type and mutants of the same developmental stage as possible. The distance from the hind limb to the anterior expression domain on the body axis was compared.

> 4\) In Figure 2---figure supplement 1, comparison of Hox gene expression patterns should be done at the same stages with similar somite numbers and the expression domain should be properly demarcated with somite \"landmarks\".

We have tried co-staining with somite markers and Hox genes, but there were technical difficulties using mouse embryos. Although the expression region was examined while confirming the somites on the photograph, no anterior shift of the expression domain was confirmed in genes except for Hoxc13 and Hoxd12.

> 5\) The readouts of genetic interaction experiments by crossing to Cbx2 mutants and RA treatment were not robust. If posterior regions were more affected, homeotic transformation in the lumbosacral regions should be shown.

At first, there were no abnormalities in the lumbosacral and caudal vertebrae in Lin28a;Cbx2 double mutant mice and RA treated Lin28a+/- embryos.

In the RA treatment experiment, no abnormalities were found in the lumbosacral and caudal vertebrae in Lin28a+/- embryos with RA. This might be due to the concentration of RA administered, but it could not be verified at higher concentrations because the fetuses died regardless of genotype.

Both Lin28a-/- mice (in this study) and Cbx2-/- mice (Coré et al., 1997; Katoh-Fukui et al., 1998, in this study) exhibited skeletal transformations in the C1/C2 region, T13/L1 region, and L6/S1 region. In the case of Lin28a;Cbx2 double mutant mice, ablation or truncation of the 13^th^ pair of ribs was observed, although the *Lin28*+/-- and *Cbx2*+/-- single mutants did not show any obvious phenotypic irregularities (Figures 3I and 3J). In the lumbosacral region, no additional phenotypes were observed in the double mutants, since almost all of the Lin28a+/- mice showed the same phenotype as the Lin28a-/- mice, which had only five lumbar vertebrae (Table 1). In caudal vertebrae, there were also no additional phenotypes in Lin28a;Cbx2 double mutant mice.

Recently, the mechanism of tail bud elongation regulation by Lin28a and Hox13 has been reported (Aires et al., 2019). According to Aires et al., Lin28a/b genes promote and Hox13 genes restrict tail bud progenitor expansion in downstream of Gdf11. Elevated Hox13 expression also directly or indirectly suppresses Lin28, leading to shortening of the tail. Since the expression of Hox13 is increased in Lin28a-/-, shortening of the tail was considered to be due to abnormal expression of Hox13. Cbx2 epigenetically suppresses Hox13, and in fact, histone modification of the Hox13 loci was altered in Lin28a-/- mice.　Thus, Lin28a/let-7-mediated Hox13 regulation by Cbx2 might be required for tail bud elongation and vertebrae formation. However, Cbx2-deficient mice did not show caudal vertebral defects and there was no effect in the tail of Lin28a/Cbx2 double mutant. These results indicate that Hox13 regulation by Lin28a occurs via both a Cbx2-dependent and -independent pathway, and might be involved in tail bud progenitor expansion. The above points are added to the revised Discussion section.

> 6\) There seems to be some discrepancy in the regulation of Hox genes by Lin28a in vitro and in vivo. For instance, Hoxa11 expression was altered in vitro, but not in the somites in development by WISH (Figure 4E).

No change in the expression domain was observed except for Hox12 and Hox13 by WISH, however, the up-regulation of many Hox genes, such as Hoxa11, was found in embryonic somites and neural tubes by qPCR. In fact, ChIP analyses showed a decrease in the repressive histone modification, H2AK119ub, confirming the increased expression of the Hox gene in embryonic somites and neural tubes. So, in terms of gene expression levels, we believe there is no contradiction between the in vivo and in vitro experiments.
